KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
Kol Lebenslauf für Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi: Einflussstatistik
Bericht ausführen
| Concept | World rank |
|---|---|
| patients placebo pellet | #1 |
| paclitaxel favor | #1 |
| numeracy benefit | #1 |
| rom leap | #1 |
| items positive indication | #1 |
| oral cryotherapy management | #1 |
| positive indication prognosis | #1 |
| fluorouracilinduced stomatitis | #1 |
| fourth treatment week | #1 |
| decrease hot | #1 |
| chemotherapy response rates | #1 |
| eortc qlqcipn20 instrument | #1 |
| dfs 5fu | #1 |
| iii double | #1 |
| sensory subscale | #1 |
| oral mucositisrelated pain | #1 |
| aes placebo arm | #1 |
| time publication attitude | #1 |
| impaired postural control | #1 |
| deprivation symptoms | #1 |
| treatment alteration | #1 |
| management hot | #1 |
| nasal vestibulitis | #1 |
| cancerrelated fatigue interventions | #1 |
| stellate ganglion block | #1 |
| small cell continuity | #1 |
| initiation tpn | #1 |
| hot flash data | #1 |
| sae δ − | #1 |
| toxicity agent | #1 |
| symptoms hormone deprivation | #1 |
| neuronal uptake transporters | #1 |
| prominent toxicity | #1 |
| postural instability chemotherapy | #1 |
| treatment symptom intervention | #1 |
| rs9657362 | #1 |
| oral cryotherapy | #1 |
| compliance institutional guidelines | #1 |
| study stool samples | #1 |
| life cipn | #1 |
| antiemetic prescribing practices | #1 |
| uncertain gbu | #1 |
| recommendation prevention | #1 |
| effects limited efficacy | #1 |
| appetite stimulation patients | #1 |
| vaginal cytology women | #1 |
| nonfluid | #1 |
| suggestion oral cryotherapy | #1 |
| individuals cipn | #1 |
| qolconclusionsthe | #1 |
| patientcompleted questionnaires | #1 |
| anthracycline data | #1 |
| topical keratolytic | #1 |
| cipn topical gel | #1 |
| median δ qs | #1 |
| placebo 15 glutathione | #1 |
| replacement testosterone andropause | #1 |
| oral mucosa study | #1 |
| leap rom | #1 |
| prevention induced cipn | #1 |
| treatment cipn | #1 |
| oxybutynin doses | #1 |
| agents cyclohexanecarboxylic | #1 |
| placebo oral mucositis | #1 |
| isae patients | #1 |
| 137 patients cycle | #1 |
| pharmacologic therapeutics | #1 |
| nonfluid weight | #1 |
| compliance institutional guideline | #1 |
| eortc cipn20 | #1 |
| 65 day | #1 |
| hot flashes day | #1 |
| n00cb | #1 |
| agents cipn | #1 |
| evidence cipn | #1 |
| n08c3 | #1 |
| newer antidepressants | #1 |
| disease patient factors | #1 |
| points doxepin | #1 |
| pharmacological targeting oct2 | #1 |
| hormone deprivation cancer | #1 |
| treatment attribution | #1 |
| cytotoxic chemotherapy supportive | #1 |
| pregabalin paclitaxel | #1 |
| glutathione cipn | #1 |
| weight loss investigation | #1 |
| judicious tpn | #1 |
| single snv rs9657362 | #1 |
| hot flashes gabapentin | #1 |
| peripheral neuropathy | #1 |
| aminobutyric acid adt | #1 |
| benefit 5fu | #1 |
| newer antidepressants gabapentin | #1 |
| ocular ice packs | #1 |
| flash score | #1 |
| ulabtka hfs | #1 |
| increased difficulty patients | #1 |
| relatedness treatment arms | #1 |
| a151408 study data | #1 |
| megestrol acetate | #1 |
| preceding 2 months | #1 |
| n08ca | #1 |
| tingling | #1 |
| bupropion nicotine dependence | #1 |
| agents humans clinicians | #1 |
| authors 30 minutes | #1 |
| nociceptors putative mechanism | #1 |
| drowsiness doxepin mouthwash | #1 |
| isae | #1 |
| flashes venlafaxine | #1 |
| anecdotal observations gabapentin | #1 |
| pilot trials efficacy | #1 |
| gait testing patients | #1 |
| extreme phenotyping | #1 |
| compounded topical gel | #1 |
| metastatic disease initiation | #1 |
| life leap | #1 |
| highdose melphalan intervention | #1 |
| flashes gabapentin | #1 |
| toxicities opioids | #1 |
| infliximab cancer | #1 |
| combination chemotherapy hec | #1 |
| leucovorin breast | #1 |
| alliance n08c1 | #1 |
| historical placebo response | #1 |
| patients megestrol acetate | #1 |
| arhgef10 cipn | #1 |
| premenopause radiotherapy | #1 |
| glutamine toxicity | #1 |
| lidocaine antacid | #1 |
| education lymphedema prevention | #1 |
| chemotherapy treatment chemotherapy | #1 |
| digital melt curve | #1 |
| hot flashes patients | #1 |
| olanzapine projects vomiting | #1 |
| flashes quality | #1 |
| a151408 | #1 |
| rose geranium | #1 |
| patients cancer anorexia | #1 |
| creatine placebo groups | #1 |
| underdescribers | #1 |
| life study arms | #1 |
| weight megestrol acetate | #1 |
| points diphenhydramine | #1 |
| modalities cancer patients | #1 |
| accru study | #1 |
| aps paclitaxel | #1 |
| tools oncologists | #1 |
| adam vte trial | #1 |
| lymphedema prevention education | #1 |
| survival tpn initiation | #1 |
| ganglion surveys humans | #1 |
| efficacy agent | #1 |
| daily questionnaires | #1 |
| safety progestational agents | #1 |
| oil nasal | #1 |
| prevention cipn | #1 |
| δ − 95 | #1 |
| underdescribers weeks | #1 |
| megestrol acetate weeks | #1 |
| benefit fluoxetine | #1 |
| stomatitis administration | #1 |
| flashes breast | #1 |
| supportive cryotherapy | #1 |
| suggestion toxicity | #1 |
| hot flashes weeks | #1 |
| cipn clinical trial | #1 |
| olanzapine arm emesis | #1 |
| placebo anecdotal observations | #1 |
| cancers prevalence | #1 |
| duloxetine response patients | #1 |
| items uncertain gbu | #1 |
| complete response authors | #1 |
| phase iii evaluation | #1 |
| flashes prospective | #1 |
| adjuvant numeracy calculators | #1 |
| ganglion surveys | #1 |
| symptom intervention | #1 |
| uncertain gbu gbu | #1 |
| chemotherapy regimen type | #1 |
| neuropathic pain difficulty | #1 |
| managing hot flashes | #1 |
| myalgias arthralgias | #1 |
| darbepoetin alfa head | #1 |
| neoplasms placebos | #1 |
| nonhormonal | #1 |
| numeracy adjuvant | #1 |
| n08cb | #1 |
| painful oxaliplatininduced cipn | #1 |
| drowsiness unpleasant taste | #1 |
| topical cannabinoids patients | #1 |
| placebo 30 points | #1 |
| adam vte | #1 |
| paclitaxel weekly cryotherapy | #1 |
| sham acupuncture participants | #1 |
| doxepin mouthwash placebo | #1 |
| antidepressants gabapentin | #1 |
| fsfi 95 | #1 |
| patients paclitaxel polyneuropathy | #1 |
| acetate hot | #1 |
| patientreported nasal symptoms | #1 |
| lymphedemafree rates | #1 |
| symptoms cipn | #1 |
| skin dermatitis trials | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| populations neurologic humans | #1 |
| paresthesia peripheral | #1 |
| hormonal ablation andropause | #1 |
| supportive nsclc | #1 |
| doxepin mouthwash patients | #1 |
| hot flash relief | #1 |
| gabapentin aminobutyric acid | #1 |
| bortezomib alters | #1 |
| oxybutynin hot flashes | #1 |
| treatment hot | #1 |
| magnesium camg | #1 |
| cancerassociated anorexia cachexia | #1 |
| udi δ − | #1 |
| recommended colorectal | #1 |
| bakplo placebo | #1 |
| diseases pilot | #1 |
| baseline week gabapentin | #1 |
| cipn20 sensory | #1 |
| hot flash control | #1 |
| hec cisplatin therapy | #1 |
| enoxaparin cvte | #1 |
| cyclohexanols female | #1 |
| efficacy gabapentin | #1 |
| accru study ru221408i | #1 |
| residual hot flashes | #1 |
| differences neuropathy syndromes | #1 |
| ctcae grade | #1 |
| pregenplus | #1 |
| balance gait testing | #1 |
| control hot flashes | #1 |
| patients underdescribers | #1 |
| cinv neoplasms vomiting | #1 |
| device 5 weeks | #1 |
| cipn function | #1 |
| patients spray product | #1 |
| flashes objective | #1 |
| burning pain | #1 |
| gabapentin hot | #1 |
| relatedness treatment | #1 |
| alleviate hot | #1 |
| paps fatigue | #1 |
| female services tpn | #1 |
| cryotherapy hands | #1 |
| active nonhormonal | #1 |
| adjuvant numeracy | #1 |
| data clinical histories | #1 |
| male megestrol megestrol | #1 |
| cipn adult | #1 |
| nonfluid bodyweights | #1 |
| vaginal dehydroepiandrosterone | #1 |
| topical cannabinoids | #1 |
| placebo pilot trials | #1 |
| cryotherapy mucositis | #1 |
| mascc isoo guidelines | #1 |
| hot flash activity | #1 |
| outcomes study points | #1 |
| hormone deprivation | #1 |
| peripheral neuropathy paclitaxel | #1 |
| acute symptoms cycle | #1 |
| ru221408i | #1 |
| therapy hot | #1 |
| neuropathy 20 | #1 |
| cisplatin therapy cinv | #1 |
| patients dosing guidelines | #1 |
| dmc mutations | #1 |
| treatments modalities | #1 |
| bothersome hot | #1 |
| antidepressive agents gamma | #1 |
| fosaprepitant isae | #1 |
| cipnmethodspatients | #1 |
| bothersome hot flashes | #1 |
| paclitaxel study arms | #1 |
| topic rectum surveys | #1 |
| cipn20 questionnaire | #1 |
| 1 month appetite | #1 |
| women 65 day | #1 |
| patients highdose interferon | #1 |
| reduction hot | #1 |
| antiserotonergic drug | #1 |
| prestudy hypothesis | #1 |
| n08cb alliance | #1 |
| antidepressant gabapentin | #1 |
| ncctg trial n06ca | #1 |
| topic peripheral neuropathy | #1 |
| hot flash frequency | #1 |
| background hot | #1 |
| burden alopecia | #1 |
| patients nasal vestibulitis | #1 |
| 2007 guidelines guideline | #1 |
| purposepaclitaxel | #1 |
| bakplo symptoms | #1 |
| cipn data | #1 |
| attribution treatment | #1 |
| amines antidepressive | #1 |
| inadequate hot | #1 |
| patients 25 micrograms | #1 |
| safety oestrogen | #1 |
| discrepancies women | #1 |
| pilot study minocycline | #1 |
| n08c1 | #1 |
| nonhormonal agent | #1 |
| inadequate control antidepressant | #1 |
| patientreported outcomes balance | #1 |
| cancer anorexia cachexia | #1 |
| physical consequences cipn | #1 |
| neuropathy data | #1 |
| numbness scores | #1 |
| numbness hands | #1 |
| induced neurotoxicity oct2 | #1 |
| supportive cytotoxic chemotherapy | #1 |
| developed mucositis | #1 |
| slight appetite stimulation | #1 |
| women male megestrol | #1 |
| dmc samples | #1 |
| incurable cancer records | #1 |
| eortc cipn | #1 |
| flaxseed hot flashes | #1 |
| placebo arms percentage | #1 |
| ulabtka placebo cream | #1 |
| numbness tingling | #1 |
| ncctg n08c3 | #1 |
| natural postural instability | #1 |
| oral cryotherapy patients | #1 |
| leap 12 months | #1 |
| aes relatedness | #1 |
| resected cutaneous melanomas | #1 |
| discrepancies clinicians assessment | #1 |
| drug humans interferons | #1 |
| shooting burning | #1 |
| purpose hot | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| gene arhgef10 | #1 |
| 81 patients patients | #1 |
| n08ca association | #1 |
| placebos pregabalin quality | #1 |
| arthralgia breast life | #1 |
| oral cryotherapy prevention | #1 |
| trust oncologists competence | #1 |
| routine feces sensitivity | #1 |
| illness neuropathic symptoms | #1 |
| cipn postural control | #1 |
| acetate anorexia | #1 |
| neoplasms climacteric | #1 |
| bellergal | #1 |
| 5 methylphenidate | #1 |
| women inadequate control | #1 |
| flashes androgen | #1 |
| centrally active agent | #1 |
| antiemetic prescribing | #1 |
| reducing hot | #1 |
| fsfi udi | #1 |
| auc cryotherapy | #1 |
| institutional guidelines patients | #1 |
| antacid mouthwash | #1 |
| alliance n08ca | #1 |
| flashes patients | #1 |
| neoplasm recurrence apixaban | #1 |
| patient followup studies | #1 |
| lenolidamide | #1 |
| nonestrogenic management | #1 |
| effects hot flashes | #1 |
| oral mucositis alopecia | #1 |
| venous toxicity fosaprepitant | #1 |
| tpn death | #1 |
| 5 weeks device | #1 |
| cachexia carcinoma life | #1 |
| 1year survival trials | #1 |
| testosterone improvements | #1 |
| udi scores baseline | #1 |
| pilot trials citalopram | #1 |
| treating institution intervention | #1 |
| 95 doxepin mouthwash | #1 |
| prevent oxaliplatin | #1 |
| 2007 guidelines suggestion | #1 |
| deprivation therapy patients | #1 |
| extensive animal data | #1 |
| progestational agents patients | #1 |
| grade peripheral neuropathy | #1 |
| or1 year patients | #1 |
| effects cipn | #1 |
| pilot trials venlafaxine | #1 |
| dronabinol combination | #1 |
| flashes pilot | #1 |
| nonhormonal agents treatment | #1 |
| neuropathic symptoms breast | #1 |
| records adult patients | #1 |
| cipn nervous diseases | #1 |
| bakplo | #1 |
| motor subscales | #1 |
| methylphenidate cancer patients | #1 |
| oncologists competence 95ci | #1 |
| lymphedema incidence intervention | #1 |
| individual patients understanding | #1 |
| cipn trials | #1 |
| purposehot | #1 |
| purposehot flashes | #1 |
| infliximab lung | #1 |
| cipn development severity | #1 |
| improvements hot flashes | #1 |
| revisitation doc | #1 |
| acceptability ssc device | #1 |
| cipn20 | #1 |
| daily hot | #1 |
| mouthwash placebo | #1 |
| − fsfi | #1 |
| patients gabapentin | #1 |
| hot flash mechanism | #1 |
| snv rs9657362 | #1 |
| conducted studies hrt | #1 |
| balance impairments patients | #1 |
| trial n00cb | #1 |
| nonhormonal hot | #1 |
| pregabalin paps | #1 |
| prognosis items | #1 |
| alleviating hot | #1 |
| ambulatory patients opioids | #1 |
| cipn20 data | #1 |
| lymphedema hrqol outcomes | #1 |
| regional hypothermia burden | #1 |
| attribution percentage | #1 |
| nonfluid weight gain | #1 |
| baseline prognosis | #1 |
| authors 115 patients | #1 |
| induced cipn | #1 |
| subsequent chemotherapy cycles | #1 |
| response relationship odc | #1 |
| gabapentin arm | #1 |
| antibiotic lozenge placebo | #1 |
| humans ganglion surveys | #1 |
| cinv day | #1 |
| suggested gabapentin | #1 |
| coasting phenomenon | #1 |
| mouthwash diphenhydramine | #1 |
| crc patients 95 | #1 |
| prevention paps | #1 |
| score baseline values | #1 |
| neuropathy prevention | #1 |
| cipnsummarythere | #1 |
| cachexia trial | #1 |
| cachexia dexamethasone | #1 |
| rs2294039 | #1 |
| 5fuinduced ocular toxicity | #1 |
| treating hot | #1 |
| anecdotal observations | #1 |
| cyproheptadine appetite | #1 |
| cipn methods | #1 |
| lignans 6 weeks | #1 |
| oestrogen hot flashes | #1 |
| megestrol acetate patients | #1 |
| patients ulabtka | #1 |
| tools hypothetical scenarios | #1 |
| cipn common | #1 |
| pilot trial hands | #1 |
| tpn longterm survival | #1 |
| flaxseed bar lignans | #1 |
| gsm fsfi | #1 |
| ssc device prototype | #1 |
| cachexia cyproheptadine | #1 |
| alliance a151724 | #1 |
| agents antihypertensive agents | #1 |
| patients dfs predictions | #1 |
| subcutaneous testosterone improvements | #1 |
| treatment hot flashes | #1 |
| polyneuropathy allelic variability | #1 |
| understanding potential benefits | #1 |
| current trial | #1 |
| data hot | #1 |
| managing hot | #1 |
| dmc assay | #1 |
| based chemotherapy isae | #1 |
| leap lymphedema | #1 |
| baseline prognosis values | #1 |
| gabapentin baseline week | #1 |
| flash therapies | #1 |
| weeks hot flashes | #1 |
| patients subcutaneous testosterone | #1 |
| flaxseed bar | #1 |
| paclitaxel polyneuropathy | #1 |
| toxicity anecdotal observations | #1 |
| dronabinol megestrol acetate | #1 |
| prominent clinical problem | #1 |
| patients 10 range | #1 |
| oestrogen survivors | #1 |
| association arhgef10 | #1 |
| flash scores | #1 |
| flashes prostate | #1 |
| hot flashes | #1 |
| recurrences clinical histories | #1 |
| minocycline cipn | #1 |
| management hot flashes | #1 |
| therapeutic targets cipn | #1 |
| rs17683288 | #1 |
| cachexia megestrol | #1 |
| difference cipn20 scores | #1 |
| numerical analogue scale | #1 |
| flashes treatment | #1 |
| doxepin mouthwash | #1 |
| hot flash | #1 |
| established cipn | #1 |
| placebo 15 points | #1 |
| alopecia ocular toxicity | #1 |
| taxane infusion | #1 |
| randomized study lymphedema | #1 |
| gabapentin hot flashes | #1 |
| hfs trial | #1 |
| baseline assessment week | #1 |
| neuropathy randomized | #1 |
| placebo drowsiness | #1 |
| stomatitis scores | #1 |
| breakthrough nausea patients | #1 |
| doubleblinded manner | #1 |
| flashes week | #1 |
| weeks hot | #1 |
| attribution clinical trials | #1 |
| taxane treatment development | #1 |
| hours nighttime sleep | #1 |
| diphenhydraminelidocaineantacid | #1 |
| vte recurrence enoxaparin | #1 |
| study dmc assay | #1 |
| pain chemotherapy | #1 |
| flashes women | #1 |
| head therapeutic equivalency | #1 |
| ulabtka | #1 |
| baseline week followup | #1 |
| n01c9 | #1 |
| rs9657362 previous study | #1 |
| women megestrol acetate | #1 |
| hormone deprivation symptoms | #1 |
| therapy numbness | #1 |
| tpn female services | #1 |
| lymphedemafree rates groups | #1 |
| 2 study arms | #1 |
| receiving fluorouracil | #1 |
| overview oncology providers | #1 |
| oncologists competence | #1 |
| suggestion pregabalin | #1 |
| dfs predictions adjuvant | #1 |
| cryotherapy auc | #1 |
| fractures infertility | #1 |
| 95 increased difficulty | #1 |
| 95 neuropathic pain | #1 |
| chemotherapy neuropathy | #1 |
| studies cyproheptadine | #1 |
| life megestrol acetate | #1 |
| favor placebo | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| paclitaxel acute | #1 |
| day cisplatin therapy | #1 |
| intervention leap | #1 |
| 8week observation period | #1 |
| acetate appetite | #1 |
| prevention oral cryotherapy | #1 |
| tpn initiation death | #1 |
| 5fu adjuvant | #1 |
| anorexia antineoplastic agents | #1 |
| n08ca patients | #1 |
| 22 nonestrogenic management | #1 |
| hot flash scores | #1 |
| phytotherapy vitamin | #1 |
| toxicity ocular | #1 |
| patients physical examinations | #1 |
| severe stomatitis | #1 |
| difficulty neuropathic pain | #1 |
| life qlqcipn20 | #1 |
| gas menopause patient | #1 |
| hfs ulabtka | #1 |
| qlq cipn20 | #1 |
| management genital symptoms | #1 |
| vitamin cipn | #1 |
| 30 points 95 | #1 |
| anorexia appetite | #1 |
| baseline neuropathic pain | #1 |
| 12 months anticoagulation | #1 |
| altered sensory organization | #1 |
| qol reported difficulty | #1 |
| leucovorin breast cancer | #1 |
| bridging editorial | #1 |
| estimated benefit dfs | #1 |
| baseline fsfi score | #1 |
| loe prevention | #1 |
| hfs symptoms patients | #1 |
| papsmethodspatients | #1 |
| alliance study a221102 | #1 |
| flashes stellate | #1 |
| gabapentin antidepressant | #1 |
| antineoplastic agents nrs | #1 |
| 43 oral complications | #1 |
| preliminary evidence improvement | #1 |
| accru trial | #1 |
| toxicity gabapentin | #1 |
| patients hot flashes | #1 |
| longitudinal continuation | #1 |
| cachexia studies | #1 |
| placebo mouthwash | #1 |
| middle aged minocycline | #1 |
| chamomile mouthwash toxicity | #1 |
| backgrounddehydroepiandrosterone | #1 |
| symptoms feet | #1 |
| duloxetine response | #1 |
| megestrol acetate nausea | #1 |
| acetate dexamethasone | #1 |
| education lymphedema education | #1 |
| hot flashes women | #1 |
| isae anthracycline | #1 |
| tingling numbness | #1 |
| preliminary promising data | #1 |
| week hot | #1 |
| uniscale qol baseline | #1 |
| alliance trial | #1 |
| symptoms hands | #1 |
| oncology providers crci | #1 |
| individuals impaired balance | #1 |
| cachexia cancer anorexia | #1 |
| acetate doses | #1 |
| 20 data patients | #1 |
| nsclc response rate | #1 |
| cipn paps | #1 |
| isaes | #1 |
| compassionate honesty | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| cvte rivaroxaban | #1 |
| fluoxetine hot | #1 |
| ocular ice | #1 |
| tested interventions lymphedema | #1 |
| joints syndrome | #1 |
| toxicity prospective trial | #1 |
| paclitaxel coasting phenomenon | #1 |
| survivors genitourinary syndrome | #1 |
| cipn phase iii | #1 |
| mascc isoo evidence | #1 |
| acute pain syndrome | #1 |
| qolresultsfrom | #1 |
| n06ca | #1 |
| hot flashes treatment | #1 |
| postsurgical neuropathic pain | #1 |
| sensory neuropathy symptoms | #1 |
| acetate versus | #1 |
| underdescribing | #1 |
| rest psychostimulants | #1 |
| nonhormonal therapies paroxetine | #1 |
| cancer hot | #1 |
| antibiotic lozenge | #1 |
| balance patientreported outcomes | #1 |
| aimss life | #1 |
| flashes common | #1 |
| prtmethodsdata | #1 |
| hot flashes quality | #1 |
| overview crci | #1 |
| pilot evaluation | #1 |
| ulabtka arm | #1 |
| chamomile mouthwash | #1 |
| male megestrol life | #1 |
| cipn agents | #1 |
| feet oxaliplatin | #1 |
| oncologists prognostic | #1 |
| placebo arm gabapentin | #1 |
| hot flashes acceptability | #1 |
| week tamoxifen | #1 |
| hot flash score | #1 |
| isae data | #1 |
| ncctg n08c1 | #1 |
| 5fuinduced stomatitis | #1 |
| nonhormonal agents | #1 |
| guidelineendorsed treatment | #1 |
| aminobutyric acid hec | #1 |
| placebo oxybutynin doses | #2 |
| worse survivorship | #2 |
| 15 points 95 | #2 |
| conceppt | #2 |
| study arms | #2 |
| n03cb | #2 |
| tamoxifenassociated hot flashes | #2 |
| ductal mometasone furoate | #2 |
| cipn prevention trials | #2 |
| sdt1 hemoccult | #2 |
| irox folfox auc | #2 |
| 432 smokers treatment | #2 |
| treatment cycles cycle | #2 |
| nonhormonal management | #2 |
| anthraquinones agents breast | #2 |
| life scrambler therapy | #2 |
| 120000 epoetin alfa | #2 |
| leucovorin women | #2 |
| oxaliplatin hands | #2 |
| substantial hot flashes | #2 |
| neuropathy paclitaxel | #2 |
| tens global impression | #2 |
| prevent paclitaxel | #2 |
| stage disease 5fu | #2 |
| descriptive manner | #2 |
| tamoxifen percentage reduction | #2 |
| 3 months bupropion | #2 |
| evaluate weight | #2 |
| day baseline week | #2 |
| hemoccultsensa sensitivity | #2 |
| improvement hot flashes | #2 |
| data gabapentin | #2 |
| cipn antineoplastic agents | #2 |
| hot flash trials | #2 |
| flash studies | #2 |
| treatment arm mmf | #2 |
| induced arthralgias | #2 |
| cisplatin polymerase inhibitors | #2 |
| mometasone time | #2 |
| positive doseresponse | #2 |
| advanced cancer anorexia | #2 |
| sdt2 hemoccult | #2 |
| trial suggestion | #2 |
| treatment smoking abstinence | #2 |
| sdt2 | #2 |
| manuscript “use | #2 |
| vte recurrence doacs | #2 |
| cohosh treatment | #2 |
| topical aged antimetabolites | #2 |
| 95 oral placebo | #2 |
| megestrol acetate dexamethasone | #2 |
| allopurinol mouthwash | #2 |
| previous hot flashes | #2 |
| middle aged survivors | #2 |
| study arms quality | #2 |
| paclitaxel induced | #2 |
| nutrition scores 95 | #2 |
| time ncctg alliance | #2 |
| dhea 4 weeks | #2 |
| acknowledged loss | #2 |
| symptoms skin toxicity | #2 |
| anabolic corticosteroid | #2 |
| duloxetine hydrochloride humans | #2 |
| placebo arms women | #2 |
| data relative benefits | #2 |
| hot flashes pregabalin | #2 |
| participants 3 stools | #2 |
| infliximab 5 day | #2 |
| venlafaxine treatment 75 | #2 |
| hot flash frequencies | #2 |
| infertility ovarian failure | #2 |
| 4 treatment weeks | #2 |
| patients difluoromethylornithine | #2 |
| cycle chronic neurotoxicity | #2 |
| induced peripheral | #2 |
| chemotherapy peripheral neuropathy | #2 |
| original report time | #2 |
| pilocarpine vaginal dryness | #2 |
| lmwh arms | #2 |
| anthrapyrazoles piroxantrone | #2 |
| study treatment citalopram | #2 |
| neuropathy cipn | #2 |
| piroxantrone women | #2 |
| illness tetracycline egfr | #2 |
| rcts preventive therapies | #2 |
| symptomatic cipn | #2 |
| reduce hot | #2 |
| incidence severity stomatitis | #2 |
| pilocarpine arms | #2 |
| symptoms surveys | #2 |
| oral megestrol | #2 |
| flashes citalopram | #2 |
| hot flashes citalopram | #2 |
| skindex16 ctcae | #2 |
| fatigue improvement methylphenidate | #2 |
| evaluating venlafaxine | #2 |
| week breast cancer | #2 |
| 01 mmf | #2 |
| screenrelevant neoplasms 16 | #2 |
| guaninemethyltransferase | #2 |
| folfox alliance | #2 |
| 108±11 | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| tingling shooting | #2 |
| indirect comparison apixaban | #2 |
| single snv | #2 |
| treatment breakthrough cinv | #2 |
| levetiracetam 4 weeks | #2 |
| versus megestrol | #2 |
| 120 arm | #2 |
| treating chemotherapy | #2 |
| shark cartilage placebo | #2 |
| patients monthly intervals | #2 |
| hot flashes humans | #2 |
| n0993 | #2 |
| venlafaxine control | #2 |
| stat itching | #2 |
| pruritus pros | #2 |
| randomized receive | #2 |
| physicians kps | #2 |
| weekly epoetin | #2 |
| folfox auc p0·0001 | #2 |
| screenrelevant neoplasms | #2 |
| iii randomized | #2 |
| intermediate term efficacy | #2 |
| preventive therapies cipn | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| differences mometasone | #2 |
| 800 liquid suspension | #2 |
| reducing chemotherapy | #2 |
| questionnaires antineoplastic agents | #2 |
| placebo pregabalin treatments | #2 |
| failure prior chemotherapy | #2 |
| epoetin alfa 40000 | #2 |
| day study week | #2 |
| life aimss | #2 |
| qol crc | #2 |
| randomized study mometasone | #2 |
| scrambler | #2 |
| circulating concentrations npy | #2 |
| cachexia acetate | #2 |
| hf frequency placebo | #2 |
| patients 40k arm | #2 |
| subsequent mucositis | #2 |
| injections hot flashes | #2 |
| palliative communications | #2 |
| day average pain | #2 |
| cipn | #2 |
| cipn cohort | #2 |
| folfox symptoms | #2 |
| women stomatitis | #2 |
| lvef 1000 | #2 |
| pregabalin hot flashes | #2 |
| surveys repeated measures | #2 |
| detection screenrelevant neoplasms | #2 |
| trial baseline week | #2 |
| 46 adenomas 1 | #2 |
| aprepitant 4 weeks | #2 |
| arms conclusions | #2 |
| scrambler therapy | #2 |
| cold items 71 | #2 |
| topic estrogen | #2 |
| patients olanzapine arm | #2 |
| patient‐physician disagreement | #2 |
| cachexia pentoxifylline | #2 |
| 979254 | #2 |
| patients black cohosh | #2 |
| cipn cancer survivors | #2 |
| ncctg trial | #2 |
| treatment minority smokers | #2 |
| females cessation treatment | #2 |
| provider assessed | #2 |
| clinically deficient fatigue | #2 |
| oxybutynin women | #2 |
| hot flashes bupropion | #2 |
| nutrition score disagreement | #2 |
| 16 hemoccult | #2 |
| placebo breast radiotherapy | #2 |
| cipn cancer treatment | #2 |
| vitamin hot flashes | #2 |
| hot flashes efficacy | #2 |
| life 4week intervention | #2 |
| hemoccultsensa sdt1 | #2 |
| decreasing stomatitis | #2 |
| appetite cachexia | #2 |
| mometasone cream | #2 |
| treatment baseline week | #2 |
| study arms tetracycline | #2 |
| tetracycline rash incidence | #2 |
| oral iron 46 | #2 |
| anemia caa | #2 |
| natural paps | #2 |
| ≤ moderate correlations | #2 |
| infliximab docetaxel | #2 |
| neoplasms double | #2 |
| stat erythema | #2 |
| starting tamoxifen | #2 |
| women rom | #2 |
| inadequate benefit | #2 |
| life venlafaxine | #2 |
| week black cohosh | #2 |
| average stomatitis sex | #2 |
| suggested agents | #2 |
| type chemotherapy drug | #2 |
| receive parenteral | #2 |
| antidepressant hot flashes | #2 |
| 95 indirect estimates | #2 |
| magnesium oxaliplatin | #2 |
| dexamethasone fluoxymesterone | #2 |
| 5fuinduced mucositis | #2 |
| patients treating institution | #2 |
| dosing zoledronic | #2 |
| hemoccultsensa sdt2 | #2 |
| longitudinal studies postmenopause | #2 |
| hot flashes data | #2 |
| months randomized | #2 |
| dhea vaginal symptoms | #2 |
| eortc qlqcipn20 | #2 |
| trials newer antidepressants | #2 |
| antidepressants hot | #2 |
| pilot citalopram | #2 |
| treatment target doses | #2 |
| treatment alterations | #2 |
| methylphenidate cancer | #2 |
| receiving megestrol | #2 |
| woman quality | #2 |
| dronabinoltreated patients | #2 |
| cipn clinical | #2 |
| control arms rate | #2 |
| 40k arm | #2 |
| clinical trials n9741 | #2 |
| cipn paclitaxel | #2 |
| paclitaxel chronic neuropathy | #2 |
| real patients treatment | #2 |
| supplementary n03cb | #2 |
| n06c4 | #2 |
| adjuvant 5fu models | #2 |
| week baseline week | #2 |
| docetaxel serum concentrations | #2 |
| hot flash studies | #2 |
| rash incidence severity | #2 |
| life cipn20 | #2 |
| cdf score | #2 |
| cipn primary outcomes | #2 |
| life illness tetracycline | #2 |
| 34—vitamin | #2 |
| increased risk cipn | #2 |
| citalopram cyclohexanols humans | #2 |
| ncctg n10c1 | #2 |
| smokers nicotine inhaler | #2 |
| intervention 18 months | #2 |
| tamoxifen medications | #2 |
| lessons cipn | #2 |
| alternative treatment regimen | #2 |
| depomedroxyprogesterone | #2 |
| hot flash diary | #2 |
| postmenopausal women previous | #2 |
| standard arm rate | #2 |
| anabolic corticosteroid appetite | #2 |
| treatment week placebo | #2 |
| hot flashes aprepitant | #2 |
| placebo vaginal dryness | #2 |
| patients oxybutynin doses | #2 |
| sensitivity cold items | #2 |
| mmf itching | #2 |
| nutrition scores physicians | #2 |
| dermatitis symptom evolution | #2 |
| peripheral neuropathy cipn | #2 |
| 120k arm | #2 |
| coriat | #2 |
| patients 120k arm | #2 |
| placebo situ carcinoma | #2 |
| breast cancer venlafaxine | #2 |
| dronabinol combination therapy | #2 |
| cipn interventions | #2 |
| placebo bar | #2 |
| anorexia antineoplastic | #2 |
| central cancer | #2 |
| 40000 40k arm | #2 |
| shark cartilage product | #2 |
| humans citalopram cyclohexanols | #2 |
| patients chemotherapyassociated anemia | #2 |
| disagreement patients | #2 |
| kps nutrition score | #2 |
| patients adjuvant 5fu | #2 |
| scrambler therapy management | #2 |
| scrambler therapy tens | #2 |
| 75 49 venlafaxine | #2 |
| stomatitis sex | #2 |
| fosaprepitant patients | #2 |
| baseline week day | #2 |
| prevalence weight concerns | #2 |
| nicotine inhaler bupropion | #2 |
| neuropathy caused | #2 |
| patients daily mmf | #2 |
| n01c4 | #2 |
| efficacy scrambler therapy | #2 |
| prevent radiation | #2 |
| glutamine placebo preparation | #2 |
| oxybutynin doses placebo | #2 |
| study n08cb alliance | #2 |
| older age bupropion | #2 |
| autonomic scales | #2 |
| established chemotherapy | #2 |
| time toxt analysis | #2 |
| vitamin hot | #2 |
| cck8 anorexia severity | #2 |
| local antineoplastic agents | #2 |
| cycle folfox | #2 |
| evaluating gabapentin | #2 |
| lamotrigine neuropathic symptoms | #2 |
| feet 18 months | #2 |
| kps nutrition scores | #2 |
| dronabinol versus | #2 |
| time toxt approach | #2 |
| 135±19 | #2 |
| alliance folfox | #2 |
| egfr inhibitor tetracycline | #2 |
| weekly hf score | #2 |
| cipn cases | #2 |
| shark cartilage patients | #2 |
| advancedstage cancer | #2 |
| poor qol 95 | #2 |
| glutathione prevention | #2 |
| starting tamoxifen women | #2 |
| appearing pilot data | #2 |
| design considerations recommendations | #2 |
| phytogenic female humans | #2 |
| induced peripheral neuropathy | #2 |
| doses megestrol | #2 |
| experience hot flashes | #2 |
| vte recurrence dalteparin | #2 |
| 16 sdt2 | #2 |
| venlafaxine gabapentin | #2 |
| desipramine hot flashes | #2 |
| cancerassociated anorexia | #2 |
| pregabalin treatments placebo | #2 |
| hemoccultsensa detection | #2 |
| historic controls npy | #2 |
| patients receiving fluorouracil | #2 |
| anorexia severity | #2 |
| women hot flashes | #2 |
| 7 control arms | #2 |
| dalteparin lowest risk | #2 |
| placebo combination therapy | #2 |
| hot flash management | #2 |
| breakthrough cinv | #2 |
| appetite dissent | #2 |
| outcome measures ctcae | #2 |
| 1 oral megestrol | #2 |
| guidelines recommendation | #2 |
| hot flash quality | #2 |
| coumarin placebo | #2 |
| fsfi score baseline | #2 |
| hemoccultsensa hemoccult | #2 |
| cipn20 scores | #2 |
| patients cipn | #2 |
| cachexia decision | #2 |
| pain ≥4 10 | #2 |
| ctcae differences | #2 |
| appetite improvement | #2 |
| life cancerrelated fatigue | #2 |
| lmwh arms 7 | #2 |
| locoregional event | #2 |
| improvement hot | #2 |
| survival 3915 patients | #2 |
| nonestrogenic hot | #2 |
| tamoxifen metabolism evidence | #2 |
| subject global impression | #2 |
| ctcae pruritus | #2 |
| flash diary | #2 |
| weight concerns 26 | #2 |
| qol hb increment | #2 |
| disagreement increased risk | #2 |
| postchemotherapy rheumatism | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| scrambler therapy treatment | #2 |
| trials suggested | #2 |
| study arms conclusions | #2 |
| sunscreen arms | #2 |
| stomatitis women | #2 |
| cipn peripheral neuropathy | #2 |
| skindex16 itching | #2 |
| anabolic corticosteroid treatment | #2 |
| product hot flashes | #2 |
| conclusions original report | #2 |
| chemotherapyassociated anemia caa | #2 |
| postural instability individuals | #2 |
| life treatment weeks | #2 |
| bupropion nicotine inhaler | #2 |
| ferric gluconate darbepoetin | #2 |
| original report mometasone | #2 |
| trial acetate doses | #2 |
| tingling patients | #2 |
| pa outcomes pros | #2 |
| npy anorexia cholecystokinin | #2 |
| folfox auc analysis | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| acttionconsortium | #2 |
| 46 screenrelevant neoplasms | #2 |
| 150 groups patients | #2 |
| 40k arm 120000 | #2 |
| appetite dissent disputes | #2 |
| mometasone surveys | #2 |
| sulfate prevent | #2 |
| singleagent megestrol acetate | #2 |
| newer antidepressants trials | #2 |
| pilocarpine vaginal | #2 |
| humans postmenopause pregabalin | #2 |
| fluoxymesterone treatment | #2 |
| citalopram hot flashes | #2 |
| management genitourinary symptoms | #2 |
| conclusions sunscreen | #2 |
| cpmp scrambler therapy | #2 |
| tens 2 weeks | #2 |
| toxicity profiles time | #2 |
| numeracy prognosis | #2 |
| gabapentin symptoms | #2 |
| gabapentin 4 weeks | #2 |
| daily mmf radiotherapy | #2 |
| 14 hot flashes | #2 |
| dna markers participants | #2 |
| detection dna markers | #2 |
| 80 anorexia | #2 |
| target doses placebo | #2 |
| mucositis 5fubased chemotherapy | #2 |
| placebo hf frequency | #2 |
| life venlafaxine hydrochloride | #2 |
| npy levels groups | #2 |
| chronic chemotherapy | #2 |
| treatment aprepitant | #2 |
| 120k arm patients | #2 |
| nonestrogenic therapies | #2 |
| oxaliplatin doses trends | #2 |
| moderate correlations ≤ | #2 |
| ecog nutrition score | #2 |
| sdt2 sdt1 | #2 |
| therapy hot flashes | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| colonoscopically normal patients | #2 |
| 5fubased chemotherapy mucositis | #2 |
| real real patients | #2 |
| aprepitan | #2 |
| time randomized study | #2 |
| flashes placebo | #2 |
| “use vitamin | #2 |
| patients shark cartilage | #2 |
| global impression life | #2 |
| pregabalin arms | #2 |
| cipn20 factor analysis | #2 |
| 49 venlafaxine | #2 |
| declining qol | #2 |
| thiophenes treatment life | #2 |
| monthly intervals appetite | #2 |
| predictors disagreement | #2 |
| cancerassociated wasting | #2 |
| usual breathing | #2 |
| neurotoxic chemotherapy cipn | #3 |
| week chemotherapy dose | #3 |
| cyproheptadine patients | #3 |
| methylphenidate patients | #3 |
| neoplasms vomiting | #3 |
| life hospice patients | #3 |
| snv charcotmarietooth disease | #3 |
| placebo prostate adenocarcinoma | #3 |
| selfreport ctcae grading | #3 |
| egfr inhibitor patients | #3 |
| life antineoplastic agents | #3 |
| n05c4 | #3 |
| purposefosaprepitant | #3 |
| n08ca n08cb study | #3 |
| inhibitorinduced rash | #3 |
| minocycline prevention | #3 |
| oxaliplatininduced neuropathy | #3 |
| thromboembolism secondary | #3 |
| carboplatin gwas | #3 |
| hgpin chemoprevention trial | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| qlqcipn20 scores | #3 |
| iii controlled | #3 |
| n08ca paclitaxel | #3 |
| placebo breast | #3 |
| primary endpoint gwas | #3 |
| “use | #3 |
| patients cancerassociated wasting | #3 |
| oxaliplatin primary endpoint | #3 |
| controlled double | #3 |
| completed diaries | #3 |
| incurable cancers | #3 |
| survivors gsm | #3 |
| hgb rbc transfusions | #3 |
| patients scrambler therapy | #3 |
| reported rash | #3 |
| intravenous calcium magnesium | #3 |
| study antidepressive agents | #3 |
| rash study arms | #3 |
| prevent epidermal | #3 |
| cmtassociated genes | #3 |
| data ginseng | #3 |
| oncology colorectal | #3 |
| drug toxicity patients | #3 |
| qlqcipn20 | #3 |
| mpa single dose | #3 |
| chlorhexidine mouthwash | #3 |
| cipn evidence | #3 |
| chronic neuropathy patients | #3 |
| mouthwash patients | #3 |
| baseline treatment day | #3 |
| rash symptoms | #3 |
| middle aged pilot | #3 |
| toxicities selfreport | #3 |
| chemotherapy‐associated anemia | #3 |
| combinationtreated arms | #3 |
| flutamide hgpin | #3 |
| additional 4 weeks | #3 |
| numeracy patients | #3 |
| trials newer | #3 |
| undergoing androgen ablation | #3 |
| hands burning pain | #3 |
| experience greater | #3 |
| depression somnolence | #3 |
| frequency hot | #3 |
| cartilage shark | #3 |
| genetic factors patients | #3 |
| 95 40 points | #3 |
| eventual sensory patients | #3 |
| snv cmtassociated genes | #3 |
| relationship numbness | #3 |
| patients upfront arm | #3 |
| hemoccult hemoccultsensa | #3 |
| experts cipn | #3 |
| canada collaborative effort | #3 |
| hot flashes trial | #3 |
| classic sums | #3 |
| 51 female age | #3 |
| corticosteroid medications | #3 |
| purposeoxaliplatin | #3 |
| vaginal dhea | #3 |
| neuropathy chemotherapy | #3 |
| epoetin alfa hgb | #3 |
| paps scores dose | #3 |
| upfront treatment arm | #3 |
| cachexia decision humans | #3 |
| n03cc | #3 |
| cold items | #3 |
| ginseng arm | #3 |
| epoetintreated patients study | #3 |
| cmt genes oxaliplatin | #3 |
| survival epa | #3 |
| female gabapentin | #3 |
| epoetintreated patients | #3 |
| acute neuropathy | #3 |
| qol placebotreated patients | #3 |
| mfsisf 4 weeks | #3 |
| apixaban lowest risk | #3 |
| interventions cancerrelated fatigue | #3 |
| real day | #3 |
| shooting burning pain | #3 |
| burning pain patients | #3 |
| fasting chemotherapy | #3 |
| dhea hot flashes | #3 |
| survival cancerassociated wasting | #3 |
| dalteparin vte | #3 |
| patients paps scores | #3 |
| crossover methodology | #3 |
| neurotoxic chemotherapies | #3 |
| asco guideline management | #3 |
| mastectomy rates | #3 |
| hemoccultsensa | #3 |
| 10 weeks therapy | #3 |
| placebo preparation | #3 |
| hormonal ablation | #3 |
| genetic predictors paclitaxel | #3 |
| fluoxetine arm | #3 |
| pts stage iii | #3 |
| thirdline hormonal therapy | #3 |
| evidence prostate adenocarcinoma | #3 |
| patients antiemetic | #3 |
| chemotherapy increases | #3 |
| projects prospective | #3 |
| sham acupuncture week | #3 |
| 95 udi | #3 |
| tamoxifen fluoxetine | #3 |
| patients lidocaine patch | #3 |
| months bupropion | #3 |
| mcbdr | #3 |
| median δ | #3 |
| bacterial agents life | #3 |
| chemotherapyassociated anemia | #3 |
| upfront arm | #3 |
| cipn cmtassociated genes | #3 |
| clonidine randomized trials | #3 |
| baseline hot | #3 |
| anorexia anorexia appetite | #3 |
| etanercept current trial | #3 |
| life eortc qlq | #3 |
| treatment bother | #3 |
| rash conclusions | #3 |
| cipn snv | #3 |
| oral megestrol acetate | #3 |
| ctpm experts | #3 |
| questionnaires syndrome paclitaxel | #3 |
| patients chemotherapy cycle | #3 |
| delayed zoledronic | #3 |
| radiation‐induced mucositis | #3 |
| trial bmd | #3 |
| ginseng crf | #3 |
| ctcae grading arms | #3 |
| epa combinationtreated arms | #3 |
| study population mcbdr | #3 |
| cipn biological targets | #3 |
| cvte | #3 |
| ” numbness | #3 |
| paps dose | #3 |
| osteoporosis osteopenia letrozole | #3 |
| 1 month cytokines | #3 |
| rash prevention | #3 |
| measures peripheral | #3 |
| centric decision | #3 |
| chemotherapy gabapentin | #3 |
| paps scores | #3 |
| ctcae pros | #3 |
| recommendations dietary counseling | #3 |
| traditional ctcae | #3 |
| data pilot trials | #3 |
| gwas mayo clinic | #3 |
| cipn ctpm | #3 |
| weekly arm differences | #3 |
| asco surveillance | #3 |
| patients cyproheptadine | #3 |
| alfa compared | #3 |
| cipn n08cx population | #3 |
| bit hands | #3 |
| 3 weeks 80k | #3 |
| physiologic pilot | #3 |
| prophylactic tetracycline | #3 |
| aminobutyric acid gabapentin | #3 |
| male megestrol | #3 |
| topic mayo clinic | #3 |
| cancer patients drugs | #3 |
| oxaliplatinbased therapy | #3 |
| receive placebo | #3 |
| chemotherapy induced | #3 |
| qol hgb | #3 |
| feet 15 | #3 |
| relationship response rate | #3 |
| tingling burning pain | #3 |
| controls singleton snv | #3 |
| combinationtreated arms survival | #3 |
| life dronabinol | #3 |
| iii evaluation | #3 |
| vitamin prevention | #3 |
| egfr inhibitorinduced rash | #3 |
| mucositis scores | #3 |
| patients baseline week | #3 |
| longitudinal adverse | #3 |
| starting letrozole | #3 |
| management cancer cachexia | #3 |
| genetic predictors cipn | #3 |
| bivariate construct | #3 |
| subcutaneous weekly | #3 |
| stomatitis sucralfate | #3 |
| advanced cancer standard | #3 |
| week venlafaxine therapy | #3 |
| delayed treatment arm | #3 |
| ≤−20 | #3 |
| n08cx | #3 |
| ssc device | #3 |
| gabapentin management | #3 |
| qlqcipn20 traditional ctcae | #3 |
| methodologic lessons | #3 |
| general subscale mfsisf | #3 |
| eightyone randomized women | #3 |
| hot flashes placebo | #3 |
| pilot trial pregabalin | #3 |
| topical ceramides | #3 |
| pilot evaluation gabapentin | #3 |
| preventing peripheral | #3 |
| follow fsfi | #3 |
| blind trial | #3 |
| cyclohexanecarboxylic acids | #3 |
| baseline general subscale | #3 |
| 40000 units | #3 |
| 20 calories | #3 |
| trials n9741 | #3 |
| acetate treated | #3 |
| ctcae grades patients | #3 |
| mcbdr primary endpoint | #3 |
| average severity | #3 |
| repeated measures analyses | #3 |
| neuropathy trials | #3 |
| pros differences | #3 |
| patient completed | #3 |
| oxaliplatin cipn | #3 |
| epoetintreated patients incidence | #3 |
| centrally active agents | #3 |
| cipn mcbdr population | #3 |
| toxicity agents | #3 |
| cmt gene | #3 |
| colorectal cancer asco | #4 |
| hot flashes week | #4 |
| nonestrogenic | #4 |
| flaxseed placebo | #4 |
| weight loss syndrome | #4 |
| or1 year | #4 |
| backgroundhistorically | #4 |
| fluorouracilbased chemotherapy | #4 |
| anorexia weight | #4 |
| doac dalteparin | #4 |
| 6 months bupropion | #4 |
| hot flashes therapy | #4 |
| toxt analysis | #4 |
| inhibitor induced | #4 |
| trpa1 cisplatin | #4 |
| 95 oral iron | #4 |
| receive oral | #4 |
| secondary vte prevention | #4 |
| arm breast neoplasms | #4 |
| followup surveillance protocol | #4 |
| egfr inhibitor rash | #4 |
| breast medical oncologists | #4 |
| survivors hot | #4 |
| administration parp inhibitor | #4 |
| odx ctx | #4 |
| qol performance score | #4 |
| ais biomarkers | #4 |
| appetite quality | #4 |
| bupropion 3 | #4 |
| controls imbalance | #4 |
| odc odc activity | #4 |
| benefits adjuvant | #4 |
| rash study | #4 |
| parenteral iron | #4 |
| endorsed treatment | #4 |
| dietician | #4 |
| cutaneous electrostimulation | #4 |
| oral cryotherapy mucositis | #4 |
| daily baseline | #4 |
| 900 dose | #4 |
| chronic neuropathy | #4 |
| nsclc trials | #4 |
| additional meta analysis | #4 |
| calgb 70305 | #4 |
| risk reduction therapy | #4 |
| therapy oncologists | #4 |
| women greater toxicity | #4 |
| baseline fatigue survival | #4 |
| qol baseline fatigue | #4 |
| hgpin antineoplastic agents | #4 |
| predictors duloxetine response | #4 |
| rash incidence | #4 |
| based chemotherapy women | #4 |
| achievements ncctg | #4 |
| mastectomy rates patients | #4 |
| nonabsorbable antibiotic | #4 |
| numbness toes | #4 |
| outcomes olanzapine | #4 |
| severity sexes | #4 |
| hec cisplatin | #4 |
| hfs quality | #4 |
| 1093 women | #4 |
| tpn initiation | #4 |
| doubleblind manner | #4 |
| 3915 patients | #4 |
| to100 | #4 |
| iron arm | #4 |
| major doselimiting toxicity | #4 |
| severe stomatitis leukopenia | #4 |
| placebo arms | #4 |
| oral cavity mucosa | #4 |
| suggested efficacy | #4 |
| topic survivors | #4 |
| flash frequency | #4 |
| prominent problem | #4 |
| day paroxetine | #4 |
| loss syndrome | #4 |
| oxybutynin placebo | #4 |
| appetite stimulation | #4 |
| cancer acute vte | #4 |
| intrapatient difference | #4 |
| chemotherapy‐induced peripheral | #4 |
| general subscale | #4 |
| addition letrozole | #4 |
| single dose venlafaxine | #4 |
| cachexia purpose | #4 |
| logistic regression incidence | #4 |
| measurable metastatic disease | #4 |
| vaginal assessment scale | #4 |
| surgery lymphedema | #4 |
| weekly toxicity | #4 |
| gabapentin day | #4 |
| recommended endorsement | #4 |
| doxepin female head | #4 |
| treatment cancer anorexia | #4 |
| cipn20 ctcae | #4 |
| 40000 | #4 |
| aimss | #4 |
| control hot | #4 |
| bupropion 3 months | #4 |
| based chemotherapy severity | #4 |
| apr dex | #4 |
| aged mouthwashes | #4 |
| placebo hot | #4 |
| paced breathing | #4 |
| treatment ncctg | #4 |
| anorexia cholecystokinin | #4 |
| hemoccult | #4 |
| publication antiemetics humans | #4 |
| anorectic cancer patients | #4 |
| odc activity mice | #4 |
| symptoms individual patients | #4 |
| recommendation ctx | #4 |
| therapy aimss | #4 |
| guidelines oral | #4 |
| ctx odx | #4 |
| cco guideline followup | #4 |
| reported hot | #5 |
| acetate neoplasms | #5 |
| physicians predictive ttr | #5 |
| women 5fu | #5 |
| mucositis allopurinol | #5 |
| hb increment | #5 |
| death communication humans | #5 |
| ttr cindices | #5 |
| agents basis | #5 |
| grade model estimates | #5 |
| receiving paclitaxel | #5 |
| physicianreported | #5 |
| cancerrelated fatigue patients | #5 |
| induced stomatitis | #5 |
| postsurgical neuropathic | #5 |
| crc cancer types | #5 |
| additional 8 weeks | #5 |
| models ttr | #5 |
| iron oral | #5 |
| race ttr | #5 |
| life epa | #5 |
| subsets treatment benefits | #5 |
| fosaprepitant prevention | #5 |
| current trial patients | #5 |
| gabapentin patients | #5 |
| acetate placebo | #5 |
| cipn effects | #5 |
| editor manuscript | #5 |
| neoplasm diagnostic tests | #5 |
| patients lmwh injections | #5 |
| nutrition scores | #5 |
| tools numeracy | #5 |
| ongoing clinical trial | #5 |
| neuropathic pain qol | #5 |
| neuropeptide leptin | #5 |
| difference control arm | #5 |
| higher drug doses | #5 |
| trials cytotoxic chemotherapy | #5 |
| kps ecog | #5 |
| mucositis caused | #5 |
| ajcc tools | #5 |
| disputes female humans | #5 |
| cipnrelated symptoms | #5 |
| libido | #5 |
| questionnaires pregabalin | #5 |
| 3 patients 4 | #5 |
| cancer survivors symptoms | #5 |
| cindices ajcc | #5 |
| cancer anorexia | #5 |
| olanzapine arm | #5 |
| nodal status stage | #5 |
| ttr variables | #5 |
| vasomotor hot flashes | #5 |
| 5fu trials | #5 |
| 3 stools | #5 |
| genetic quality life | #5 |
| acetate neoplasms quality | #5 |
| impaired postural | #5 |
| cyclohexanecarboxylic | #5 |
| treating postmenopausal | #5 |
| ajcc external validation | #5 |
| major outcome measure | #5 |
| appetite enhancement | #5 |
| nodal status grade | #5 |
| pain scores dose | #5 |
| trial developed | #5 |
| life lmwh | #5 |
| progestational agent | #5 |
| fluoxymesterone patients | #5 |
| numeracy tools | #5 |
| fiftynine percent | #5 |
| cipn participants | #5 |
| ttr ajcc | #5 |
| aapro | #5 |
| reduce chemotherapy | #5 |
| cisplatin ganglia | #5 |
| rectal cancer surveillance | #5 |
| medical oncology outpatients | #5 |
| groups leptin concentrations | #5 |
| gabapentin trial | #5 |
| sham real | #5 |
| oxantrazole | #5 |
| neoplasms compared | #5 |
| cachexia anorexia | #5 |
| treatment benefits sex | #5 |
| odx | #5 |
| cumulative neurotoxicity | #5 |
| colorectal cancer society | #5 |
| neuropathy acute | #5 |
| numeracy online clinical | #5 |
| colorectal cancer surveillance | #5 |
| trial gabapentin | #5 |
| combination electroacupuncture | #5 |
| study dmc | #5 |
| trials lessons | #5 |
| ajcc version staging | #5 |
| bone loss osteopenia | #5 |
| intravenous calcium | #5 |
| digital melt | #5 |
| centrally active | #5 |
| discontinuation aimss | #5 |
| flashes data | #5 |
| epa supplement | #5 |
| cipn numbness | #5 |
| patient outcomes numeracy | #5 |
| trial hot | #5 |
| placebo exposed | #5 |
| crc cancers | #5 |
| data supporting | #6 |
| therapy 10 weeks | #6 |
| longacting methylphenidate | #6 |
| imidazoles letrozole | #6 |
| methylo | #6 |
| hospitalized oncology patients | #6 |
| intervention lymphedema | #6 |
| death kps | #6 |
| pharmaceutic aged aged | #6 |
| paclitaxel peripheral neuropathy | #6 |
| selective poly | #6 |
| placebo arm patients | #6 |
| severity neuropathic symptoms | #6 |
| 500 mcg | #6 |
| nicotine inhaler | #6 |
| studies vomiting | #6 |
| megestrol | #6 |
| loe guidelines | #6 |
| staging patient outcomes | #6 |
| inhaler bupropion | #6 |
| mri trends | #6 |
| her2directed therapy | #6 |
| 4week intervention | #6 |
| rs11572080 | #6 |
| placebo hot flashes | #6 |
| flashes humans | #6 |
| versus combination | #6 |
| proportion aes | #6 |
| fatigue pilot study | #6 |
| medical acupuncture | #6 |
| severity data | #6 |
| nonanthracycline chemotherapy | #6 |
| placebo hfs | #6 |
| hrqol breast neoplasms | #6 |
| daily diary questionnaires | #6 |
| participants sham acupuncture | #6 |
| cancerrelated fatigue life | #6 |
| olanzapine prevention | #6 |
| neurological safety | #6 |
| bf qol | #6 |
| highly emetogenic chemotherapy | #6 |
| apixaban cancer patients | #6 |
| nci ctcae | #6 |
| life toxicity | #6 |
| agents breast | #6 |
| sadenosyllmethionine treatment | #6 |
| sensory scale | #6 |
| 5fu folfox | #6 |
| predictive illness surveys | #6 |
| north central | #6 |
| alliance clinical | #6 |
| 71 sensitivity | #6 |
| wisconsin ginseng | #6 |
| breakthrough nausea | #6 |
| induced sensory | #6 |
| 5fubased chemotherapy | #6 |
| cipn treatment | #6 |
| active malignancy | #6 |
| depomedroxyprogesterone acetate | #6 |
| background chemotherapy | #6 |
| smoking abstinence rates | #6 |
| study arms difference | #7 |
| follow year | #7 |
| induced rash | #7 |
| mpa arm | #7 |
| weight concerns smokers | #7 |
| odx score | #7 |
| patients oral cryotherapy | #7 |
| transdermal clonidine | #7 |
| mucositis placebo | #7 |
| cancer patients anorexia | #7 |
| induced neuropathy | #7 |
| throat discomfort | #7 |
| incidence rbc transfusion | #7 |
| cmt genes | #7 |
| stage nodal status | #7 |
| outcomes primary outcomes | #7 |
| cryotherapy arm | #7 |
| prevalence moderatetosevere | #7 |
| illness antimetabolites | #7 |
| symptom subscale | #7 |
| cyclophosphamidedoxorubicin | #7 |
| neuropathy oxaliplatin | #7 |
| intermediate odx | #7 |
| paclitaxel peripheral | #7 |
| vte recurrence doac | #7 |
| hemoccult hemoquant | #7 |
| patients hb response | #7 |
| fluoxetine clinical trials | #7 |
| blind study | #7 |
| 1week baseline period | #7 |
| weekly epoetin alfa | #7 |
| sensitivity fecal | #7 |
| bupropion relapse | #7 |
| accru | #7 |
| serum concentrations cytokines | #7 |
| uniscale | #7 |
| venlafaxine therapy | #7 |
| 20 percent placebo | #7 |
| placebocontrolled trial | #7 |
| 12 treatment arms | #7 |
| pregabalin prevention | #7 |
| appetites | #7 |
| pain cipn | #7 |
| smoking 3 | #7 |
| nausea cancer patients | #7 |
| menopause hot | #7 |
| model estimates survival | #7 |
| lower extremity symptoms | #7 |
| adjuvant interferon patients | #7 |
| toxic polyneuropathy | #7 |
| minority smokers | #7 |
| 5fu based chemotherapy | #7 |
| nutrition score | #7 |
| patient anthracycline | #7 |
| intervention lymphedema status | #7 |
| study drug trial | #7 |
| venlafaxine day | #7 |
| patients product | #7 |
| letrozole differences | #7 |
| rs10509681 | #7 |
| scheduled receive | #7 |
| uniscale qol | #7 |
| hemoquant | #7 |
| lymphedema education | #7 |
| week followup | #7 |
| cream versus | #7 |
| skindex16 | #7 |
| fuinduced | #7 |
| citalopram cyclohexanols | #7 |
| venlafaxine versus | #7 |
| chronic postmastectomy pain | #7 |
| anecdotal | #8 |
| oxaliplatin paclitaxel | #8 |
| odx risk | #8 |
| factors cipn | #8 |
| raw data trials | #8 |
| libido women | #8 |
| paclitaxel pain | #8 |
| recurrence colon cancer | #8 |
| paclitaxel severity | #8 |
| epa survival | #8 |
| venlafaxine hot flashes | #8 |
| stomatitis patients | #8 |
| 1355 | #8 |
| sdt1 | #8 |
| smokers weight concerns | #8 |
| induced painful | #8 |
| series clinical trials | #8 |
| direct oral factor | #8 |
| cycle capecitabine | #8 |
| fecal blood | #8 |
| venous toxicity | #8 |
| neuropathy scale | #8 |
| oxaliplatin neuropathy | #8 |
| 18 months symptoms | #8 |
| oral placebo | #8 |
| tamoxifeninduced hot flashes | #8 |
| antidepressant patients | #8 |
| mouth sores | #8 |
| agents newer | #8 |
| neuropathic symptoms | #8 |
| placebo suggestion | #8 |
| chronic neurotoxicity | #8 |
| cancer survivors cipn | #8 |
| treatment cinv | #8 |
| oral iron placebo | #8 |
| cpmp | #8 |
| neuropathy pain | #8 |
| greater toxicity | #8 |
| severe hot flashes | #8 |
| topic antineoplastic | #8 |
| progestational | #8 |
| placebo pilot study | #8 |
| opioids moderate pain | #8 |
| symptoms neuropathy | #8 |
| life antibodies | #8 |
| women hfs | #8 |
| folfox dfs | #8 |
| flutamide placebo | #8 |
| prior chemotherapy exposure | #8 |
| 70305 | #8 |
| evidence pharmacologic interventions | #8 |
| administered systemically | #8 |
| nonhormonal treatments | #8 |
| pros aes | #8 |
| efficacy newer antidepressants | #8 |
| questionnaires syndrome | #9 |
| medications evidence | #9 |
| antiemetic properties | #9 |
| appetite weight | #9 |
| cancer patients cipn | #9 |
| vitality subscale | #9 |
| radiationinduced esophagitis | #9 |
| disease recurrence recurrence | #9 |
| patients hot | #9 |
| 5 nausea | #9 |
| apixaban lower rate | #9 |
| acid amines | #9 |
| lmwh injections | #9 |
| oxaliplatin placebo | #9 |
| cutaneous aged anesthetics | #9 |
| prevention vomiting | #9 |
| 43 trials | #9 |
| fosaprepitant | #9 |
| topical antimetabolites | #9 |
| incurable disease | #9 |
| sensory axonopathy | #9 |
| incidence colorectal adenomas | #9 |
| flash control | #9 |
| neuropathic symptoms patients | #9 |
| lamotrigine pain | #9 |
| fatigue methylphenidate | #9 |
| letrozole day | #9 |
| genistein tumor growth | #9 |
| disease receive | #9 |
| follow tests | #9 |
| trial paroxetine | #9 |
| surgical year | #9 |
| relapse relapse prevention | #9 |
| mucositis pain | #9 |
| lymphedema hrqol | #9 |
| cipn patients | #9 |
| numbness fingers | #9 |
| skindex16 scores | #9 |
| baseline week week | #9 |
| study treatment arm | #9 |
| flashes hot | #9 |
| dose dfmo | #9 |
| mometasone furoate placebo | #9 |
| ambulatory analgesics | #9 |
| patients provided | #9 |
| lymphedema prevention | #9 |
| aged pilot | #9 |
| hot flashes tamoxifen | #9 |
| controlled randomized | #10 |
| randomized placebo | #10 |
| asco guideline | #10 |
| gabapentin | #10 |
| oxaliplatin trpa1 | #10 |
| aprepitant treatment | #10 |
| δ − | #10 |
| frequency hot flashes | #10 |
| megestrol acetate quality | #10 |
| shark cartilage | #10 |
| life dietary supplements | #10 |
| data relatedness | #10 |
| phase iii | #10 |
| qol total | #10 |
| advanced cancer life | #10 |
| nonhormonal therapies | #10 |
| cancerrelated fatigue fatigue | #10 |
| patients neurotoxic chemotherapy | #10 |
| minocycline reduction | #10 |
| oxaliplatin peripheral | #10 |
| neoplasms neuralgia | #10 |
| pain medications patients | #10 |
| recommendations general population | #10 |
| anorexia cachexia | #10 |
| chemotherapy‐induced | #10 |
| ecog kps | #10 |
| adult cancers | #10 |
| sensitivity cancer | #10 |
| humans megestrol | #10 |
| physical consequences | #10 |
| folfox 5fu | #10 |
| incidence stomatitis | #10 |
| vaginal dryness | #10 |
| 40 arm | #10 |
| combination therapy relapse | #10 |
| qol anemia | #10 |
| antineoplastic agents humans | #10 |
| symptomatic malignant ascites | #10 |
| cancerassociated anemia | #10 |
| cognitive chemotherapy | #10 |
| flash data | #10 |
| nonhormonal treatment | #10 |
| life topic reproducibility | #10 |
| inhibit cyp2d6 | #10 |
| doses citalopram | #10 |
| venlafaxine arm | #10 |
| scrambler therapy patients | #10 |
| ctcae grades | #10 |
| trials demonstrated | #10 |
| factes | #10 |
| differences 5 years | #10 |
| patients treatment period | #10 |
| antiemetic guidelines | #11 |
| erythropoietic response | #11 |
| sensory neurotoxicity | #11 |
| difficulty patients | #11 |
| efficacy black cohosh | #11 |
| promising data | #11 |
| qol uniscale | #11 |
| hydrazine sulfate | #11 |
| olanzapine chemotherapy | #11 |
| melt curve | #11 |
| cancer undergoing | #11 |
| nicotine patch therapy | #11 |
| dalteparin major bleeding | #11 |
| diphenhydramine lidocaine | #11 |
| flashes | #11 |
| translational component | #11 |
| differences study arms | #11 |
| vomiting cancer patients | #11 |
| reported incidences | #11 |
| physicians increased risk | #11 |
| ativan | #11 |
| curve assay | #11 |
| anastrozole 10 | #11 |
| institutional guideline | #11 |
| prevalence neuropathic pain | #11 |
| electroanalgesia | #11 |
| ginseng placebo | #11 |
| fsfi female | #11 |
| combination treated | #11 |
| gbu | #11 |
| completed daily | #12 |
| venlafaxine hydrochloride | #12 |
| leptin cck8 | #12 |
| −307 | #12 |
| decreased libido | #12 |
| recurrence comparisons | #12 |
| valerian placebo | #12 |
| breast cancer letrozole | #12 |
| irox folfox | #12 |
| ctpm | #12 |
| pilot trial levetiracetam | #12 |
| probability prospective studies | #12 |
| hot flashes 95 | #12 |
| cipn development | #12 |
| cachexia clinical trials | #12 |
| venlafaxine women | #12 |
| apixaban dalteparin | #12 |
| gait testing | #12 |
| toxicities groups | #12 |
| hb response | #12 |
| individuals advanced adenomas | #12 |
| toxicity 4 weeks | #12 |
| adjuvant communication decision | #12 |
| patients cipn symptoms | #12 |
| oxaliplatin induced | #12 |
| reported peripheral | #12 |
| capsaicin cream | #12 |
| pluronic lecithin organogel | #12 |
| neurotoxic chemotherapy | #12 |
| rash quality | #12 |
| cycles drugs | #12 |
| nausea patients | #13 |
| newer antidepressants placebo | #13 |
| treatment advanced cancer | #13 |
| troublesome symptoms | #13 |
| anemia life | #13 |
| 10 range | #13 |
| megestrol acetate therapy | #13 |
| patients advancedstage cancer | #13 |
| adjuvant colon cancer | #13 |
| patients diphenhydramine | #13 |
| months smoking | #13 |
| hot flashes baseline | #13 |
| adenomas aspirin | #13 |
| trial support | #13 |
| andropause | #13 |
| initial 3 months | #13 |
| life investigation | #13 |
| valerian sleep | #13 |
| severity hot flashes | #13 |
| ais women | #13 |
| venlafaxine life | #13 |
| venlafaxine paroxetine | #13 |
| ncctg | #13 |
| 40 points 95 | #13 |
| education clinical practice | #13 |
| troubling | #13 |
| life neoplasm recurrence | #13 |
| weight cachexia | #13 |
| median hb | #13 |
| autonomic scale | #13 |
| neuropathy outcome | #13 |
| bmd 1 year | #13 |
| oral anesthetics | #13 |
| improve cancer | #13 |
| common toxicity | #13 |
| paroxetine hot flashes | #13 |
| rs3213619 | #13 |
| acute treatment vte | #13 |
| therapy benefits | #13 |
| patients breakthrough cinv | #13 |
| 2000 update | #13 |
| abh gel | #13 |
| incident exposure | #13 |
| major bleeding doac | #13 |
| adjuvant benefit | #13 |
| flashes day | #13 |
| neuropathic pain surgery | #13 |
| estimates prognosis | #13 |
| prophylactic agent | #14 |
| phase 3 months | #14 |
| provided data | #14 |
| recurrences patients | #14 |
| oral iron | #14 |
| palliate | #14 |
| flash activity | #14 |
| life anemia | #14 |
| oxaliplatin vivo | #14 |
| biomarkers bone formation | #14 |
| based topical | #14 |
| stool dna | #14 |
| benefit toxicity | #14 |
| patients pain scores | #14 |
| genital symptoms | #14 |
| 5fu surgery | #14 |
| fluoxymesterone | #14 |
| smokers placebo | #14 |
| marked toxicity | #14 |
| diagnosis localized disease | #14 |
| bfq | #15 |
| androgen ablation therapy | #15 |
| advanced cancer methods | #15 |
| prognosis quality life | #15 |
| week baseline | #15 |
| adjuvant aromatase | #15 |
| advanced malignant disease | #15 |
| agents life | #15 |
| life life survivors | #15 |
| taste alterations | #15 |
| grade age | #15 |
| suggestion guideline | #15 |
| aes treatment | #15 |
| sternal skin conductance | #15 |
| treatment weeks patients | #15 |
| vaginal dryness dyspareunia | #15 |
| 16–28 | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| persistent incisional pain | #15 |
| folfox irox | #15 |
| evidence treatment options | #15 |
| syndromes peripheral | #15 |
| trials gabapentin | #15 |
| acute diarrhea patients | #15 |
| acceptability device | #15 |
| therapy nicotine | #15 |
| highly emetogenic | #15 |
| academic oncologists | #15 |
| lidocaine patch | #15 |
| triazoles zoledronic | #15 |
| duloxetine cipn | #15 |
| monoclonal carcinoma antibodies | #15 |
| week darbepoetin | #15 |
| mastectomy irradiation | #15 |
| clinician perception | #15 |
| product time | #16 |
| tingling pain | #16 |
| symptoms numbness | #16 |
| venlafaxine patients | #16 |
| endpoints baseline | #16 |
| mfsi | #16 |
| patients venlafaxine | #16 |
| female cancer survivors | #16 |
| paclitaxel oxaliplatin | #16 |
| antiemetic agent | #16 |
| findings education | #16 |
| loss appetite | #16 |
| measurable evaluable disease | #16 |
| stool dna test | #16 |
| premenopausal women chemotherapy | #16 |
| dalteparin 95 | #16 |
| diarrhoea time | #16 |
| vte apixaban | #16 |
| breast gynecologic cancer | #16 |
| rash pruritus | #16 |
| treatment cancer vte | #16 |
| randomized trial aspirin | #16 |
| induced hot | #16 |
| patch therapy | #16 |
| advancedstage cancer patients | #16 |
| reduction fatigue | #17 |
| recommendation suggestion | #17 |
| screen detection | #17 |
| arthralgias | #17 |
| vaginal symptoms | #17 |
| breast cancer oestrogen | #17 |
| rs11849538 | #17 |
| oxaliplatin doses | #17 |
| inadequate control | #17 |
| crc patients patients | #17 |
| study tetracycline | #17 |
| leptin concentrations groups | #17 |
| 18 months women | #17 |
| cancer menopause | #17 |
| institute common | #17 |
| oxaliplatin treated | #17 |
| arhgef10 | #17 |
| flashes tamoxifen | #17 |
| device women | #17 |
| leap study | #17 |
| 786 patients | #17 |
| women metastatic | #17 |
| fractional co2 | #17 |
| dfs folfox | #17 |
| venlafaxine | #17 |
| adenomas 1 | #17 |
| patients informed decisions | #18 |
| oncology providers patients | #18 |
| sternal skin | #18 |
| prophylactic antiemetic therapy | #18 |
| patients overview | #18 |
| patients irox | #18 |
| patients hb | #18 |
| symptoms hormone | #18 |
| mri mastectomy | #18 |
| severity cipn | #18 |
| data followup | #18 |
| baseline 4 | #18 |
| receiving head | #18 |
| intervention guidelines | #18 |
| subsets age | #18 |
| 120000 | #18 |
| secondary endpoint analysis | #18 |
| sigmoidoscopy tomography | #18 |
| oral dronabinol | #18 |
| standard prognostic | #18 |
| flash frequencies | #18 |
| postmenopausal women letrozole | #18 |
| treatment osteopenia | #18 |
| severity hot | #18 |
| menopausal problems | #18 |
| placebo 04 | #18 |
| randomized trials women | #18 |
| 5 adjuvant | #18 |
| n6 n5 | #19 |
| physician reported | #19 |
| panax quinquefolius | #19 |
| groups infliximab | #19 |
| rs7349683 | #19 |
| 7 outcomes | #19 |
| previous colorectal | #19 |
| oxaliplatin neurotoxicity | #19 |
| life gabapentin | #19 |
| induced mucositis | #19 |
| 95 46 | #19 |
| neoplasms peripheral | #19 |
| acute cancer | #19 |
| double blinded | #19 |
| flash reduction | #19 |
| bmd neoplasms chemotherapy | #19 |
| evidence status | #19 |
| oxaliplatin carboplatin | #19 |
| folfox fluorouracil | #19 |
| treatment mastectomy | #19 |
| mastectomy methotrexate | #19 |
| ncdf | #19 |
| patients based chemotherapy | #19 |
| unpleasant taste | #19 |
| minimal adverse effects | #19 |
| appetite nutritional status | #20 |
| diseases randomized | #20 |
| fatigue 4 | #20 |
| placebo smokers | #20 |
| progestational agents | #20 |
| numbness | #20 |
| pilot trials | #20 |
| emetogenic chemotherapy | #20 |
| life skindex16 | #20 |
| placebo cream | #20 |
| fecal occult | #20 |
| cancer cancer therapy | #20 |
| advanced cancer study | #20 |
| receiving pelvic | #20 |
| therapeutic options treatment | #20 |
| major bleeding treatment | #20 |
| surveillance protocol | #20 |
| study ginseng | #20 |
| baseline week | #20 |
| revisitation | #20 |
| reducing pain | #20 |
| palliating | #20 |
| moderate pain patients | #20 |
| routine test | #21 |
| metastatic breast carcinoma | #21 |
| chemotherapy agents | #21 |
| refractory cachexia | #21 |
| cipn symptoms | #21 |
| acetate patients | #21 |
| receptorpositive breast cancer | #21 |
| female menopause | #21 |
| oral mucositis pain | #21 |
| therapy adverse effects | #21 |
| cancer starting | #21 |
| radiationinduced dermatitis | #21 |
| treatment options women | #21 |
| studies methylphenidate | #21 |
| substantial problem | #21 |
| management cachexia | #21 |
| trial 12 months | #21 |
| crossover analysis | #21 |
| scores ≤ | #22 |
| doc time | #22 |
| candidate single | #22 |
| asco panel | #22 |
| emetogenic | #22 |
| optumlabs | #22 |
| crossover phase | #22 |
| pharmacokinetics infliximab | #22 |
| guideline intervention | #22 |
| n9741 | #22 |
| projects quality | #22 |
| subcutaneous testosterone | #22 |
| severity adverse events | #22 |
| location stage | #22 |
| patients testosterone | #22 |
| npy leptin | #22 |
| 150 groups | #22 |
| median time initiation | #22 |
| gain patients | #22 |
| patients 5 weeks | #22 |
| 5 pounds | #23 |
| detecting recurrence | #23 |
| sucralfate patients | #23 |
| versus delayed | #23 |
| fsdsr | #23 |
| mascc isoo | #23 |
| stool dna testing | #23 |
| mcf7 cells genistein | #23 |
| decision adjuvant | #23 |
| potential toxicities | #23 |
| acupuncture hot | #23 |
| life ascites | #23 |
| aes qol | #23 |
| followup tests | #23 |
| acetate middle | #23 |
| abstract5fluorouracil | #24 |
| apixaban treatment | #24 |
| replacement testosterone | #24 |
| aged anorexia | #24 |
| prevention chemotherapy | #24 |
| ortho biotech | #24 |
| randomized 1 | #24 |
| day chemotherapy | #24 |
| weeks primary | #24 |
| every3 | #24 |
| pilot clinical | #24 |
| n56 | #24 |
| tamoxifen octreotide | #24 |
| aged amines | #24 |
| adjuvant decision making | #24 |
| female hot | #24 |
| mirtazapine patients | #24 |
| design rcts | #24 |
| topic design severity | #24 |
| hrt survival | #24 |
| vte trial | #25 |
| antiepileptic agent | #25 |
| mmf placebo | #25 |
| institutional guidelines | #25 |
| bpisf | #25 |
| cancerassociated weight loss | #25 |
| women adjuvant tamoxifen | #25 |
| doses schedules | #25 |
| neoplasia screening | #25 |
| lymphedema incidence | #25 |
| severe nausea vomiting | #25 |
| nausea olanzapine | #25 |
| prevention nausea | #25 |
| trial pilot | #25 |
| qol tools | #25 |
| recommendations basis | #25 |
| criteria adverse | #25 |
| placebo arm treatment | #25 |
| cco guideline | #25 |
| irradiation mastectomy | #26 |
| induced musculoskeletal | #26 |
| joints muscles | #26 |
| colorectal adenomas patients | #26 |
| regional breast | #26 |
| agents prevention | #26 |
| combination weight loss | #26 |
| receiving oxaliplatin | #26 |
| mfsisf | #26 |
| oncology journals | #26 |
| 2005 update | #26 |
| prior week | #26 |
| syndrome menopause | #26 |
| nci ctc | #26 |
| aiinduced | #26 |
| neoplasms estrogens | #26 |
| trial evaluate | #26 |
| dose gabapentin | #26 |
| clinical trials chemotherapy | #26 |
| treatment arms | #26 |
| undergoing adjuvant | #26 |
| cachexia carcinoma | #26 |
| lymphedema arm | #27 |
| adjuvant 5fu | #27 |
| recommendations trials | #27 |
| series trials | #27 |
| patients short term | #27 |
| neuropathy symptoms | #27 |
| hot flashes hf | #27 |
| prophylactic antiemetic | #27 |
| fubased | #27 |
| events ctcae | #27 |
| nurse survey | #27 |
| antiemetic | #27 |
| lmwh survival | #27 |
| valerian | #27 |
| smoking bupropion | #27 |
| definitively | #28 |
| describers | #28 |
| lidocaine patches | #28 |
| fluoxetine citalopram | #28 |
| treatment hot flushes | #28 |
| newer | #28 |
| gynecologic cancer survivors | #28 |
| muscles joints | #28 |
| primary endpoint proportion | #28 |
| standard prognostic factors | #28 |
| alliance | #28 |
| matched general population | #28 |
| prevent colorectal adenomas | #28 |
| mastectomy rate | #28 |
| chest rays | #28 |
| intractable palliative | #28 |
| mucositis study | #29 |
| pain cancer survivors | #29 |
| biological predictors | #29 |
| difluoromethylornithine dfmo | #29 |
| statistical controversies | #29 |
| vitamin incidence | #29 |
| citalopram placebo | #29 |
| survival arms | #29 |
| chemotherapy cipn | #29 |
| asco guideline update | #29 |
| paclitaxel cipn | #29 |
| points study | #29 |
| taxanebased chemotherapy | #29 |
| patients paclitaxel | #29 |
| efficacy venlafaxine | #29 |
| placebo arm | #29 |
| blood screening | #29 |
| feet hands | #29 |
| smokers bupropion | #29 |
| usual oncology | #30 |
| cipn pain | #30 |
| management oral mucositis | #30 |
| diseases peripheral | #30 |
| small pilot | #30 |
| development cipn | #30 |
| alfa darbepoetin | #30 |
| anthrapyrazoles | #30 |
| benadryl | #30 |
| postmenopause predictive | #30 |
| contralateral axillary | #30 |
| twoyear followup | #30 |
| phase iii comparison | #30 |
| month duration | #30 |
| mild nausea | #30 |
| loss postmenopausal | #30 |
| middle aged postmenopause | #30 |
| pain oral | #30 |
| sixtysix patients | #31 |
| efficacy methylphenidate | #31 |
| treatment acute vte | #31 |
| treatment paclitaxel | #31 |
| term rectal | #31 |
| arms placebo | #31 |
| management menopausal symptoms | #31 |
| mastectomy mri | #31 |
| symptomatic ascites | #31 |
| middle aged perimenopause | #31 |
| benefit dfs | #31 |
| ixabepilone patients | #31 |
| pain quality life | #31 |
| calcium magnesium | #31 |
| patients races | #31 |
| prevention oral mucositis | #31 |
| patients secondary analysis | #31 |
| breast cancer symptoms | #32 |
| receiving highly | #32 |
| vera gel | #32 |
| doubleblind trial | #32 |
| guideline endorsement | #32 |
| women lymphedema | #32 |
| female services | #32 |
| oncologist patients | #32 |
| rash severity | #32 |
| evidencebased guidance | #32 |
| camg | #32 |
| delayed chemotherapy | #32 |
| fingers hands | #33 |
| instruments life | #33 |
| dose megestrol | #33 |
| blind manner | #33 |
| breast neoplasms life | #33 |
| acupuncture hot flashes | #33 |
| pursuant | #33 |
| aloe vera gel | #33 |
| week treatment | #33 |
| chemotherapeutic regimens | #33 |
| survival advanced cancer | #33 |
| smokers randomized | #33 |
| painful cipn | #33 |
| 4week followup | #33 |
| increased difficulty | #33 |
| hands feet | #33 |
| therapy bupropion | #33 |
| toxicity breast | #33 |
| neoplasms carboplatin | #33 |
| isoo | #33 |
| patients cinv | #33 |
| questionnaires total | #33 |
| patients taxol | #33 |
| sensitivity polyps | #33 |
| neuropathy patients | #33 |
| patients acitretin | #34 |
| continuation study | #34 |
| patients nausea | #34 |
| toxicity fluorouracil | #34 |
| chemotherapy hec | #34 |
| cipn severity | #35 |
| trial designed | #35 |
| moderatetosevere patients | #35 |
| major bleeding lmwh | #35 |
| primary outcomes trials | #35 |
| prevention chemotherapyinduced nausea | #35 |
| dawley statistics | #35 |
| formal consensus process | #35 |
| 4 week | #35 |
| cancer international society | #35 |
| stomatitis | #35 |
| treating cancer | #35 |
| inhibitors venlafaxine | #35 |
| patients tools | #35 |
| levels week | #35 |
| carcinoembryonic antigen levels | #35 |
| united states hrqol | #35 |
| head neck radiotherapy | #36 |
| nk1ras | #36 |
| lymphedema treatment | #36 |
| mometasone placebo | #36 |
| myalgias | #36 |
| doxepin | #36 |
| pain pilot | #36 |
| cohosh | #36 |
| pyrexia patients | #36 |
| secondary prevention measures | #36 |
| tnfα study | #36 |
| stages colorectal cancer | #36 |
| cancerrelated fatigue | #37 |
| global impression | #37 |
| nausea neoplasms | #37 |
| topic stomatitis | #37 |
| symptoms cancer | #37 |
| survival supportive | #37 |
| topic humans life | #37 |
| chronic nausea | #37 |
| p00052 | #37 |
| early integrated | #37 |
| ctcae | #37 |
| planned sample size | #37 |
| mc5 | #37 |
| alleviation | #37 |
| study intravenous | #37 |
| patients taxanes | #38 |
| oncology providers | #38 |
| relationships populations | #38 |
| sensitization nociceptors | #38 |
| women metastatic disease | #38 |
| 5ht3ras | #38 |
| illness purpose | #38 |
| fluorouracil based | #38 |
| tests controlled trials | #38 |
| trial conducted | #38 |
| individual item | #38 |
| patients highdose melphalan | #38 |
| crushed ice | #39 |
| chi2 tests | #39 |
| trials oncology | #39 |
| arm difference | #39 |
| grade 2 toxicity | #39 |
| blind crossover | #39 |
| european organisation cancer | #39 |
| cohort type | #39 |
| 3 agents | #39 |
| menopause gsm | #39 |
| treatment breakthrough | #39 |
| qol clinical trials | #39 |
| acids drug | #39 |
| arm placebo | #39 |
| study double | #39 |
| topic reproducibility surveys | #40 |
| single dose placebo | #40 |
| prevent colorectal | #40 |
| cachexia clinical | #40 |
| arthralgia breast | #40 |
| initial mastectomy | #40 |
| terminology criteria | #40 |
| appetite patients | #40 |
| patients lamotrigine | #40 |
| mastectomy chemotherapy | #40 |
| method fatigue | #40 |
| difluoromethylornithine | #40 |
| treatment analyses | #40 |
| relapse 3 months | #41 |
| drug evaluation studies | #41 |
| smokers weight | #41 |
| bupropion smokers | #41 |
| trial performed | #41 |
| symptoms 12 months | #41 |
| united states guidelines | #41 |
| zoledronic acid bmd | #41 |
| gabapentin placebo | #41 |
| undergoing androgen | #41 |
| treatment period | #41 |
| cure recurrence | #41 |
| nortriptyline placebo | #42 |
| patients incurable | #42 |
| placebo venlafaxine | #42 |
| patients completed | #42 |
| location age | #42 |
| chemotherapy day | #42 |
| neuronal protection | #42 |
| transdermal gel | #42 |
| treating institution | #42 |
| randomized doubleblind trial | #42 |
| oral gabapentin | #42 |
| appetite body | #42 |
| postsurgical | #43 |
| sex location | #43 |
| baseline fatigue | #43 |
| median weight | #43 |
| dietary supplements life | #43 |
| desipramine patients | #43 |
| preliminary insights | #43 |
| 5 induced | #43 |
| highdose interferon | #43 |
| pain reduction patients | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| nonpain | #44 |
| risk cipn | #44 |
| collaborative effort | #44 |
| surveillance united states | #44 |
| trial benefit | #44 |
| bupropion placebo | #44 |
| vaginal moisturizer | #44 |
| disagreement | #44 |
| weeks efficacy | #44 |
| outcome gamma | #44 |
| sensory symptoms | #44 |
| ginseng panax quinquefolius | #45 |
| menogaril | #45 |
| conclusion trial | #45 |
| rash grade | #45 |
| historic controls | #45 |
| 5 years incidence | #45 |
| acute pain patients | #45 |
| survivors colorectal cancer | #45 |
| humans peripheral | #45 |
| objective tumor regression | #45 |
| fisher tests | #45 |
| piroxantrone | #45 |
| genitourinary syndrome menopause | #45 |
| patients advanced adenomas | #46 |
| current manuscript | #46 |
| acute skin toxicity | #46 |
| item measures | #46 |
| radiotherapy randomized | #46 |
| adverse symptoms | #46 |
| randomized comparison | #46 |
| middle aged patient | #46 |
| phase iii life | #46 |
| putative mechanism | #46 |
| vaccines melanoma | #46 |
| factor prognostic | #46 |
| cisplatin neuropathy | #46 |
| megestrol acetate treatment | #46 |
| epoetin alfa placebo | #46 |
| nonpharmacological therapy | #46 |
| longitudinal methods | #46 |
| chemotherapy antineoplastic | #46 |
| study gaba | #46 |
| clinical problem | #46 |
| iii colon cancer | #46 |
| radiationinduced oral mucositis | #46 |
| aged mometasone | #47 |
| screening setting | #47 |
| twopart | #47 |
| darbepoetin alfa patients | #47 |
| dose paclitaxel | #47 |
| neoplasms parenteral nutrition | #47 |
| average pain | #47 |
| mascc | #47 |
| bipn | #47 |
| cachexia female | #47 |
| genetic predictors | #47 |
| differences pros | #47 |
| oxybutynin | #48 |
| menopause life | #48 |
| neck radiotherapy | #48 |
| genitourinary symptoms | #48 |
| nausea day | #48 |
| stratification factor | #48 |
| qol female humans | #48 |
| placebo gabapentin | #48 |
| physical examinations | #48 |
| chemotherapy nausea | #49 |
| flie | #49 |
| patientclinician communication | #49 |
| female cancer | #49 |
| sham arm | #49 |
| cancer survivors fatigue | #50 |
| models stage | #50 |
| antiserotonergic | #50 |
| receiving androgen | #50 |
| pain numbness | #50 |
| time conclusions | #50 |
| hot flashes hfs | #50 |
| replens | #50 |
| mastectomy pain | #50 |
| cachexia | #50 |
| placebos randomized | #50 |
| patients cancer pain | #51 |
| regional hypothermia | #51 |
| transdermal testosterone | #51 |
| blinded placebo | #51 |
| effective treating | #51 |
| patients 8 weeks | #51 |
| cisplatin humans | #51 |
| genitourinary syndrome | #51 |
| vomiting chemotherapy | #51 |
| trastuzumab orr | #52 |
| aged orchiectomy | #52 |
| risk bone loss | #52 |
| treatment adt | #52 |
| metaanalysis incidence | #52 |
| management chemotherapy | #52 |
| black cohosh | #52 |
| 80k | #52 |
| differences treatment arms | #52 |
| toxicity time | #53 |
| nervous peripheral | #53 |
| potential adjuvant | #53 |
| purposepatients | #53 |
| control nausea | #53 |
| tamoxifen antineoplastic agents | #53 |
| cancer venous | #53 |
| receiving radiotherapy | #53 |
| antiemetics antineoplastic | #54 |
| treatment months | #54 |
| double‐blind trial | #54 |
| life topic humans | #54 |
| standard placebo | #54 |
| severe hot | #54 |
| recurrent disease | #54 |
| levetiracetam treatment | #54 |
| pilot trial | #54 |
| 20 data | #54 |
| blood testing | #54 |
| bupropion treatment | #55 |
| serial levels | #55 |
| acupuncture cancer | #55 |
| treatment tobacco dependence | #55 |
| cachexia therapy | #55 |
| fatigue inventory | #55 |
| cancerdirected therapy | #55 |
| scalp cooling | #55 |
| symptoms therapy | #55 |
| symptoms hot | #56 |
| xaliproden | #56 |
| adjuvant endocrine treatment | #56 |
| undergoing chemotherapy | #56 |
| carboplatin female humans | #56 |
| diseases antineoplastic | #56 |
| time placebo | #56 |
| adjuvant colon | #57 |
| recurrence symptoms | #57 |
| benefit scale | #57 |
| common terminology | #57 |
| 12 courses | #57 |
| placebo solution | #57 |
| ferric gluconate | #58 |
| cachexia weight loss | #58 |
| undergoing treatment | #58 |
| quality life questionnaire | #58 |
| skin dermatitis | #58 |
| pain peripheral | #58 |
| limited degree | #58 |
| topical gel | #58 |
| points placebo | #58 |
| compared oral | #58 |
| completion adjuvant chemotherapy | #58 |
| major bleeding enoxaparin | #58 |
| patients hec | #59 |
| placebo citalopram | #59 |
| chemotherapy cognitive | #59 |
| ocular irritation | #59 |
| safety rivaroxaban | #59 |
| chemotherapyinduced nausea | #59 |
| data understanding | #59 |
| coprescription | #59 |
| osteopaenia | #59 |
| weight appetite | #59 |
| serotonergic effects | #60 |
| anticonvulsants antidepressive | #60 |
| colonoscopically | #60 |
| study medication | #60 |
| hb baseline | #60 |
| patients mirtazapine | #60 |
| pipn | #61 |
| lymphedema women | #61 |
| paroxetine fluoxetine | #61 |
| bleomycin patients | #61 |
| standard dosing | #61 |
| tamoxifen metabolism | #61 |
| sensitivity individuals | #61 |
| emla cream | #61 |
| 3 randomized | #61 |
| caregivers pain | #61 |
| doubleblind | #61 |
| topic surveys life | #61 |
| cancer patients study | #61 |
| 1 week treatment | #61 |
| induced taste | #62 |
| efficacy fluoxetine | #62 |
| venlafaxine placebo | #62 |
| fluorouracil induced | #62 |
| dermatological toxicities | #62 |
| chemotherapy dose | #62 |
| alpha weight | #62 |
| recurrent disease patients | #62 |
| ocular toxicity | #62 |
| pain bleeding | #62 |
| ncictc | #63 |
| 105 months | #63 |
| integrative oncology | #63 |
| prior chemotherapy regimen | #63 |
| antibodies monoclonal carcinoma | #63 |
| lessen | #63 |
| aged placebos | #63 |
| anorexia patients | #63 |
| patients disease recurrence | #63 |
| versus placebo | #64 |
| aged nausea | #64 |
| improvement sexual function | #64 |
| bupropion nicotine | #64 |
| carboplatin oxaliplatin | #64 |
| incidence rash | #64 |
| treatment chemotherapy | #64 |
| rivaroxaban enoxaparin | #64 |
| patients cancer types | #64 |
| cyproheptadine | #64 |
| allelic variability | #64 |
| painful peripheral neuropathy | #64 |
| cyclohexanols | #64 |
| alleviate | #64 |
| survivorship issues | #65 |
| validated patient | #65 |
| agents double | #65 |
| 4 weeks week | #65 |
| dalteparin treatment | #65 |
| efficacy toxicity | #65 |
| appetite weight loss | #65 |
| patients minocycline | #65 |
| administration paclitaxel | #65 |
| patients comparisons | #65 |
| 75 daily | #65 |
| study gabapentin | #66 |
| diseases neoplasms | #66 |
| oncology clinical | #66 |
| food intake patients | #66 |
| acetate therapy | #66 |
| placebo months | #66 |
| nicotine nasal | #66 |
| life topic | #67 |
| clinician training | #67 |
| qol fatigue | #67 |
| estrogen suppression | #67 |
| target doses | #67 |
| prevention smoking | #68 |
| induced dermatitis | #68 |
| cachexia weight | #68 |
| pilocarpine treatment | #68 |
| 46 95 | #68 |
| hec | #68 |
| baseline study | #68 |
| patients randomized | #68 |
| subcutaneous dalteparin | #68 |
| hormonal therapies | #68 |
| skin surveys | #69 |
| vasomotor symptoms women | #69 |
| ongoing loss | #69 |
| debilitating | #69 |
| fsfi score | #69 |
| gained weight | #69 |
| women ais | #70 |
| surgery cancer | #70 |
| nonsignificant trends | #70 |
| multifactorial syndrome | #70 |
| development severity | #70 |
| induced ovarian | #70 |
| item score | #70 |
| chemotherapy anemia | #70 |
| life referral | #71 |
| week percentage | #71 |
| weight compared | #71 |
| anthrapyrazole | #71 |
| incidence severity | #71 |
| major bleeding apixaban | #71 |
| infliximab combination | #71 |
| oral drug administration | #72 |
| patients pilot | #72 |
| trials planning | #72 |
| effects ginseng | #72 |
| placebo patches | #72 |
| humans lignans | #72 |
| systemic retinoids | #72 |
| cisplatin treated | #72 |
| prospective pilot trial | #73 |
| weeks placebo | #73 |
| chemoprevention trial | #73 |
| ginseng treatment | #73 |
| chemotherapy supportive | #73 |
| placebo | #73 |
| ergotamines | #73 |
| stage primary | #73 |
| rash | #74 |
| qli | #74 |
| rcts systematic reviews | #74 |
| receiving chemotherapy | #74 |
| women estrogen therapy | #74 |
| dronabinol | #74 |
| fractional co2 laser | #74 |
| trial evaluating | #74 |
| anemia antineoplastic | #74 |
| 353 patients | #75 |
| prevention | #75 |
| nervous diseases | #75 |
| cancerrelated fatigue crf | #75 |
| acid supplement | #75 |
| cycles cycle | #76 |
| blind clinical | #76 |
| weekly arm | #76 |
| acute skin | #76 |
| inhibitors tamoxifen | #76 |
| 95 01 | #77 |
| dose 90 | #77 |
| hospice staff | #77 |
| week p005 | #77 |
| anorexia weight loss | #77 |
| breast cancer paclitaxel | #77 |
| alliance patients | #77 |
| anemia darbepoetin | #77 |
| tamoxifen postmenopausal | #77 |
| cancer randomized | #77 |
| female humans insurance | #78 |
| patients zoledronic acid | #78 |
| values data | #78 |
| tamoxifen postmenopausal women | #78 |
| 3 arm | #78 |
| patients darbepoetin alfa | #79 |
| pain syndrome | #79 |
| week schedule | #79 |
| efficacy lamotrigine | #79 |
| serum concentrations infliximab | #79 |
| symptoms sensitivity | #79 |
| surgery year | #79 |
| vte recurrence | #79 |
| therapy antineoplastic | #79 |
| life phase iii | #80 |
| foot syndrome | #80 |
| zoledronic acid treatment | #80 |
| vomiting antiemetics | #80 |
| week 4 | #80 |
| isoflavone supplements | #80 |
| time mastectomy | #80 |
| patients treatment arms | #81 |
| study march | #81 |
| lowmolecular weight heparin | #81 |
| patient qol | #81 |
| guideline recommendation | #81 |
| period crossover | #81 |
| oral oncology | #81 |
| bupropion smoking | #82 |
| greater weight gain | #82 |
| suggestion | #82 |
| paroxetine patients | #82 |
| backgroundchemotherapy | #82 |
| standard clinical | #82 |
| orbital stability | #83 |
| trpv1 trpa1 | #83 |
| recommendations article | #83 |
| patients participating | #83 |
| day weeks | #83 |
| zinc sulfate | #84 |
| method female | #84 |
| cinv patients | #84 |
| trpm8 trpa1 | #84 |
| ice pack | #85 |
| systematic reviews rcts | #85 |
| neoplasm metastasis neoplasms | #85 |
| cancer weight | #85 |
| mayo clinic | #86 |
| cryotherapy patients | #86 |
| receiving placebo | #86 |
| treatment nicotine dependence | #86 |
| ttf survival | #86 |
| therapyinduced | #87 |
| pilot study safety | #87 |
| frequency severity | #87 |
| life cachexia | #87 |
| week 5 | #87 |
| serum hepcidin levels | #87 |
| baseline arms | #87 |
| nicotine nasal spray | #87 |
| methodspatients | #87 |
| primary symptom | #87 |
| incidence osteoporosis | #87 |
| acp documentation | #88 |
| anecdotal reports | #88 |
| integrative therapies | #88 |
| putative mediator | #89 |
| cancer vte | #89 |
| treatment fatigue | #89 |
| iu daily | #89 |
| morphine pharmacokinetics | #90 |
| male chemotherapy | #90 |
| clinical oncology asco | #90 |
| outcome venlafaxine | #90 |
| tolerated patients | #91 |
| arm treatment | #91 |
| ncorp | #91 |
| delayed cinv | #91 |
| endoxifen concentrations | #91 |
| symptoms including | #91 |
| scores placebo | #91 |
| iii efficacy | #91 |
| patients paroxetine | #92 |
| patients upfront | #92 |
| completion chemotherapy | #92 |
| cisplatin oxaliplatin | #92 |
| trials treatment | #92 |
| nerve pain | #92 |
| ameliorating | #93 |
| neoplasms quality life | #94 |
| quiet stance | #94 |
| breast cancer survivors | #94 |
| questionnaires survival | #94 |
| anemic patients | #94 |
| apixaban dose | #94 |
| 1 primary | #94 |
| duloxetine hydrochloride | #94 |
| mometasone | #94 |
| arm 3 | #94 |
| alfa patients | #95 |
| patients appetite | #95 |
| common symptoms | #95 |
| cancerrelated pain | #95 |
| ccop | #96 |
| patients completion | #96 |
| 0 10 | #96 |
| failure chemotherapy | #96 |
| prevention management | #96 |
| hlaa2 patients | #96 |
| mayo clinic rochester | #96 |
| udi | #96 |
| adjuvant therapy survival | #97 |
| acute vte | #97 |
| pyrexia | #97 |
| oral mucositis patients | #97 |
| paclitaxel patient | #97 |
| treatment tolerability | #98 |
| text review | #98 |
| agents paclitaxel | #98 |
| completed study | #98 |
| preliminary data | #98 |
| painful area | #98 |
| alleviating | #98 |
| crnmb | #98 |
| identical placebo | #98 |
| 15 points | #98 |
| topic cyclophosphamide | #99 |
| patient questionnaires | #99 |
| fatigue insomnia | #99 |
| bcca | #99 |
| 5fu leucovorin | #99 |
| 4 weeks baseline | #99 |
| difference incidence | #99 |
| patient medical | #99 |
| induced esophagitis | #99 |
| pregnadienediols | #99 |
| 5fluorouracil oxaliplatin | #99 |
| clinician communication | #100 |
| oncology outpatients | #100 |
| qlq | #100 |
| 10 doses | #100 |
| survival nsclc | #100 |
| male sex factors | #100 |
| 275 patients | #101 |
| antineoplastic agents life | #101 |
| oncology clinicians | #101 |
| lung cancer chemoprevention | #101 |
| nortriptyline | #101 |
| postresection | #101 |
| 5 based | #101 |
| humans life | #101 |
| lidocaine lidocaine | #101 |
| oncology asco | #101 |
| placebo 1 year | #102 |
| methods trial | #102 |
| reported effects | #103 |
| variance clinical trials | #103 |
| races ethnicities | #104 |
| 3106 | #104 |
| patients anorexia | #104 |
| purposeprevious | #104 |
| quality life data | #104 |
| leap | #105 |
| 12 24 months | #105 |
| diseases treatment | #105 |
| phytogenic clinical trials | #105 |
| chemotherapy cycle | #105 |
| patients 150 | #105 |
| neuropathy | #106 |
| trial studies | #106 |
| dalteparin patients | #106 |
| dfmo | #106 |
| months relapse | #106 |
| nutritional determinants | #106 |
| infusion site | #106 |
| compounds oxaliplatin | #106 |
| stool samples patients | #106 |
| epoetin alfa patients | #107 |
| cycle cycles | #107 |
| valeriana officinalis | #107 |
| versus dexamethasone | #107 |
| humans menopause | #107 |
| pain intensity ratings | #107 |
| urogenital diseases | #107 |
| anastrozole letrozole | #107 |
| life topic severity | #108 |
| women experience | #108 |
| week study | #108 |
| relapse prevention | #108 |
| breast cancer tamoxifen | #108 |
| time toxicity | #108 |
| female urogenital | #109 |
| mouthwash | #109 |
| women vasomotor symptoms | #109 |
| strong prognostic factor | #109 |
| levocarnitine | #109 |
| treatment cancer pain | #109 |
| patients guideline | #109 |
| patients cancer treatment | #110 |
| combined paclitaxel | #110 |
| clinic rochester | #110 |
| oxaliplatin therapy | #110 |
| life adverse events | #110 |
| vomiting adult | #111 |
| egfr inhibitor | #111 |
| cmf chemotherapy | #111 |
| prevention bone loss | #111 |
| insomnia pain | #112 |
| function suppression | #112 |
| dosing schedules | #112 |
| adverse events ctcae | #113 |
| –iii | #113 |
| agents hormonal | #113 |
| reassess | #113 |
| treatment arms patients | #113 |
| patients arms | #113 |
| colorectal neoplasia | #113 |
| visits patient | #113 |
| vaginal diseases | #113 |
| functional iron deficiency | #113 |
| vestibulitis | #113 |
| therapy induced | #114 |
| hfsd | #114 |
| cachexia humans | #114 |
| patients olanzapine | #114 |
| alopecia patients | #114 |
| diseases breast | #114 |
| dietary lignans | #114 |
| acitretin | #114 |
| months 3 | #114 |
| qol patient | #114 |
| single nucleotide variants | #114 |
| studies randomized | #115 |
| combination nicotine | #115 |
| laser therapy lasers | #115 |
| rivaroxaban venous | #115 |
| letrozole tamoxifen | #115 |
| patients anthracycline | #115 |
| crci | #115 |
| placebo postmenopausal women | #116 |
| treatment arm | #116 |
| patients peripheral neuropathy | #117 |
| nk1 receptor antagonist | #117 |
| induction ornithine decarboxylase | #117 |
| 2007 guidelines | #117 |
| oral factor | #117 |
| symptoms chemotherapy | #117 |
| recurrence diagnosis | #118 |
| oral antineoplastic agents | #118 |
| appetite stimulant | #118 |
| noradrenaline reuptake | #119 |
| preventive therapies | #119 |
| patients weekly paclitaxel | #119 |
| 3915 | #119 |
| trpa1 trpv1 | #119 |
| diseases pain | #119 |
| trials conducted | #119 |
| 750 day | #120 |
| participants arms | #120 |
| definition classification | #120 |
| treatment weeks | #120 |
| clinical histories | #120 |
| olanzapine placebo | #120 |
| original report | #120 |
| resultswhile | #120 |
| patients cancers | #121 |
| induced ocular | #121 |
| placebo double | #121 |
| untoward | #121 |
| fullerton | #121 |
| postmenopausal postmenopause | #121 |
| hormonal agents | #121 |
| cancer multiple | #122 |
| nervous agents | #122 |
| oxaliplatin folfox | #122 |
| netupitant | #123 |
| stable dose | #123 |
| objective review | #123 |
| acute oral | #123 |
| rolapitant | #123 |
| surgery analysis | #123 |
| skin pain | #123 |
| cancer quality | #123 |
| weeks 4 | #123 |
| isoflavones genistein | #124 |
| treatment letrozole | #124 |
| rivaroxaban compared | #124 |
| pros baseline | #124 |
| survivors breast cancer | #124 |
| neuropathic pain patients | #124 |
| patients diploid tumors | #124 |
| 1 month patients | #125 |
| 90 dose | #125 |
| week dose | #125 |
| factors odds | #126 |
| neurotoxic agents | #126 |
| resultsfour | #126 |
| patients physicians | #127 |
| genetic quality | #127 |
| promising agents | #127 |
| hormonal breast | #127 |
| fsfi | #127 |
| recurrent adenomas | #127 |
| anorexia | #127 |
| diagnosis metastatic disease | #127 |
| arms patients | #128 |
| uncommon variants | #128 |
| belladonna | #128 |
| cancerassociated vte | #128 |
| weight concerns | #128 |
| alfa erythropoietin | #128 |
| neoplasms quality | #129 |
| resultsforty | #129 |
| 5 leucovorin | #129 |
| agents neoplasms | #129 |
| postural instability | #129 |
| vomiting cinv | #129 |
| clinical trial patients | #129 |
| control arms | #130 |
| serum baseline | #130 |
| patientreported outcome | #130 |
| problem patients | #130 |
| cancer fatigue | #131 |
| prognostic variables | #131 |
| function fsfi | #131 |
| treatment toxicities | #131 |
| 150 iu | #131 |
| bmd tscore | #131 |
| neurotoxicity syndromes | #132 |
| cancerrelated symptoms | #132 |
| efficacy vitamin | #132 |
| relapse smoking | #132 |
| onycholysis | #132 |
| pilot data | #132 |
| progress report | #133 |
| topical treatment | #133 |
| cachexia patients | #133 |
| assessable | #133 |
| endodermal sinus tumor | #134 |
| 5 placebo | #134 |
| symptom control | #134 |
| ganglion block | #134 |
| ginseng panax | #134 |
| agents generation | #135 |
| cancers patients | #135 |
| common adverse effects | #135 |
| chemotherapy 5 | #135 |
| 150 women | #135 |
| cold hyperalgesia | #135 |
| toxt | #135 |
| bmd postmenopausal women | #135 |
| weekly therapy | #136 |
| patientlevel pooled analysis | #136 |
| symptomatic benefit | #136 |
| bothersome | #136 |
| painful neuropathy | #136 |
| npy levels | #136 |
| severe fatigue | #137 |
| percentage reduction | #137 |
| life physical function | #137 |
| study trials | #137 |
| substantial benefit | #137 |
| stage cancer | #137 |
| poor qol | #137 |
| intrapatient | #137 |
| agents bortezomib | #137 |
| zoledronic | #138 |
| accrued | #138 |
| grade stage | #138 |
| hfs patients | #138 |
| chemoprevention studies | #139 |
| advanced lung | #139 |
| therapy breast | #139 |
| underwent mastectomy | #139 |
| incurable cancer | #139 |
| factbr | #139 |
| patients advanced cancer | #140 |
| liquid suspension | #140 |
| breast chest wall | #140 |
| oxaliplatin chemotherapy | #141 |
| patients placebo | #141 |
| paclitaxel weekly | #141 |
| patients levetiracetam | #142 |
| disclose | #142 |
| tamoxifen placebo | #142 |
| financial concerns | #142 |
| fluorouracil 5 | #143 |
| protocols breast | #143 |
| medicine clinical | #143 |
| european organisation | #144 |
| preoperative magnetic | #144 |
| snv | #144 |
| allopurinol placebo | #144 |
| vaginal cytology | #145 |
| evidence loe | #145 |
| debilitating condition | #145 |
| fluorouracil humans | #145 |
| agents bone | #145 |
| eortc qlq | #145 |
| surgery type | #146 |
| eligible women | #146 |
| oral olanzapine | #148 |
| backgroundwomen | #148 |
| volatile plants | #148 |
| dietary counselling | #148 |
| desipramine treatment | #149 |
| numeracy | #149 |
| venlafaxine treatment | #150 |
| adjuvant systemic | #150 |
| n201 | #150 |
| predict recurrence | #150 |
| daily diaries | #151 |
| multinational association | #151 |
| prior chemotherapy regimens | #151 |
| intravenous access | #151 |
| methodologic | #151 |
| response rate survival | #151 |
| patients receive | #151 |
| women estrogen | #151 |
| 14 week | #152 |
| tumor recurrence patients | #152 |
| caa patients | #152 |
| balance impairments | #152 |
| oral mucositis | #152 |
| ovarian function suppression | #152 |
| groups symptoms | #152 |
| cramping | #153 |
| 80 dose | #154 |
| carboplatin trastuzumab | #154 |
| dermatomes | #155 |
| cindices | #155 |
| adjuvant systemic therapy | #155 |
| combination chemotherapy cisplatin | #156 |
| integrated palliative | #156 |
| mangafodipir | #156 |
| hyperalimentation | #156 |
| life randomized | #156 |
| infliximab 5 | #156 |
| fsds | #156 |
| vinblastine bleomycin | #156 |
| methods randomized | #156 |
| common terminology criteria | #157 |
| breast cancer trastuzumab | #157 |
| gait stability | #157 |
| racially diverse | #157 |
| women breast carcinoma | #157 |
| oncology study | #158 |
| arm versus | #158 |
| study initiation | #158 |
| vomiting nausea | #158 |
| induced nausea | #159 |
| physicians patients | #159 |
| iii clinical | #159 |
| chemotherapy breast cancer | #159 |
| survivors colorectal | #159 |
| weekly doses | #159 |
| treatment postmenopausal women | #160 |
| stellate ganglion | #160 |
| paclitaxel taxol | #160 |
| european organisation treatment | #160 |
| major problem | #160 |
| chemotherapy quality | #160 |
| cancer pain patients | #160 |
| estrogen depletion | #161 |
| risk infertility | #161 |
| women hormone therapy | #161 |
| validity life | #161 |
| data efficacy | #163 |
| neoplasms pain | #164 |
| efficacy women | #164 |
| mometasone furoate | #165 |
| cisplatin vinblastine | #165 |
| current project | #165 |
| patients 1 month | #166 |
| pharmacokinetic analyses | #166 |
| skeletal events | #166 |
| illness surveys questionnaires | #167 |
| life topic surveys | #167 |
| osteoporosis prevention | #167 |
| chemotherapy‐induced nausea | #168 |
| direct inhibitors | #168 |
| anthracycline | #168 |
| chemotherapy groups | #168 |
| dosing patients | #169 |
| menopause symptoms | #169 |
| patients data | #169 |
| patients adenomas | #169 |
| 432 patients | #169 |
| management chronic pain | #170 |
| ixabepilone | #170 |
| rochester | #171 |
| disease cmt | #171 |
| global quality | #171 |
| prospective clinical trials | #171 |
| daily placebo | #171 |
| chemotherapy completion | #172 |
| prestudy | #172 |
| label pilot | #173 |
| hot flushes | #173 |
| lamotrigine placebo | #173 |
| 1 year therapy | #173 |
| placebos | #173 |
| impaired balance | #173 |
| judicious | #173 |
| diarrhoea patients | #174 |
| phase iii trial | #174 |
| methylphenidate placebo | #174 |
| pilot feasibility study | #174 |
| prospective evaluation | #174 |
| physician order | #175 |
| male breast cancer | #175 |
| cancer cancer treatment | #175 |
| decreased quality | #175 |
| arthralgia | #175 |
| baseline weight | #176 |
| weeks women | #177 |
| treatment 14 | #177 |
| life assessments | #177 |
| thirty percent | #178 |
| bodyweights | #178 |
| treatmentrelated toxicity | #179 |
| life baseline | #179 |
| bothered | #179 |
| bolus fluorouracil | #179 |
| expected benefits | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| darbepoetin | #182 |
| ginseng | #182 |
| gain weight | #182 |
| escalations | #182 |
| oxaliplatin 5fluorouracil | #182 |
| organisation treatment | #183 |
| peri postmenopausal women | #183 |
| toxicity criteria | #183 |
| prognostic criteria | #184 |
| received oral | #184 |
| acetyll | #184 |
| tube primary | #184 |
| infliximab antibodies | #184 |
| acute pain | #184 |
| biostatisticians | #184 |
| effects chemotherapy | #184 |
| white smokers | #184 |
| outcome measures life | #185 |
| additional chemotherapy | #185 |
| reported sexual | #185 |
| arm volume | #186 |
| patients drug | #187 |
| treatment 4 weeks | #187 |
| cinv | #187 |
| delayed nausea | #187 |
| treating | #187 |
| strong prognostic | #188 |
| tamoxifen letrozole | #188 |
| reduction therapy | #188 |
| troublesome | #188 |
| lessened | #188 |
| week follow | #188 |
| management breast cancer | #188 |
| adjuvant decision | #188 |
| oxaliplatin dose | #189 |
| aching | #189 |
| neoplasia female humans | #189 |
| week 1 | #190 |
| protocol therapy | #190 |
| aged nitriles | #190 |
| placebo study | #190 |
| survivors breast | #190 |
| antiemetic regimens | #190 |
| cancer cancer survivors | #191 |
| twentyfive patients | #191 |
| completed baseline | #191 |
| aspirin incidence | #192 |
| patients increases | #192 |
| treatment cancer patients | #192 |
| chronic lymphedema | #192 |
| toxicity patients | #192 |
| manuscript | #192 |
| aches | #192 |
| fortysix patients | #192 |
| assigned receive | #193 |
| cimicifuga racemosa | #193 |
| humans isoflavones | #193 |
| 25 women | #194 |
| weekly trastuzumab | #194 |
| effective agents | #194 |
| weight loss patients | #195 |
| pain breast | #195 |
| ornithine decarboxylase activity | #195 |
| 3 fatty | #195 |
| acids double | #196 |
| resultsdata | #196 |
| palonosetron dexamethasone | #197 |
| trial designs | #197 |
| pituitaryadrenal axis | #197 |
| toxicity profiles | #198 |
| postmenopausal patients | #198 |
| resultstwo | #198 |
| surveillance strategy | #198 |
| women menopause | #199 |
| organization treatment | #199 |
| culminates | #199 |
| nicotine patch | #199 |
| patients letrozole | #199 |
| accent | #199 |
| delayed emesis | #199 |
| percent reduction | #200 |
| adjuvant interferon | #200 |
| oral glutamine | #201 |
| menopause premature | #201 |
| primary goal | #202 |
| greater 5 | #202 |
| treatment bmd | #202 |
| imiquimod | #202 |
| item responses | #202 |
| treatment week | #202 |
| hormonal treatments | #203 |
| cancer anemia | #203 |
| bmd postmenopausal | #203 |
| composition cachexia | #204 |
| treated placebo | #204 |
| plo | #204 |
| pelvic radiation therapy | #204 |
| induced oral | #205 |
| placebo 8 | #206 |
| unwilling | #206 |
| dalteparin | #206 |
| udi6 | #206 |
| leucovorin patients | #206 |
| chemotherapy drugs | #206 |
| pharmacologic interventions | #207 |
| heat hyperalgesia | #207 |
| mice cisplatin | #207 |
| 4 8 weeks | #208 |
| reduced food intake | #208 |
| incurable | #208 |
| humans leucovorin | #208 |
| chemotherapy | #209 |
| hands patients | #209 |
| 5 daily | #209 |
| lamotrigine | #210 |
| estrogen receptor modulators | #210 |
| controlled evaluation | #210 |
| methotrexate 5 | #210 |
| gel application | #211 |
| diagnosis recurrence | #212 |
| vomiting patients | #212 |
| initials | #212 |
| methodsthis | #212 |
| regionally advanced | #212 |
| charcotmarietooth disease | #213 |
| trial vitamin | #213 |
| docetaxel cyclophosphamide | #213 |
| placebo 6 weeks | #214 |
| patient weight | #214 |
| oncology practices | #214 |
| dexamethasone control | #214 |
| december patients | #215 |
| antiemetic therapy | #215 |
| olanzapine 5 | #215 |
| oxaliplatin | #215 |
| 15 minutes | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| women breast cancer | #217 |
| patients duloxetine | #217 |
| tamoxifen users | #217 |
| women tamoxifen | #217 |
| gabapentin humans | #217 |
| aprepitant | #218 |
| purposethe purpose | #218 |
| placebo weeks | #218 |
| 10 daily | #218 |
| current management | #218 |
| —reply | #218 |
| nonmajor | #218 |
| hot | #218 |
| life humans | #219 |
| nmscs | #219 |
| transdermal fentanyl | #219 |
| palliative oncology | #219 |
| nonabsorbable | #220 |
| sublingual administration | #220 |
| sexual symptoms | #220 |
| moderate pain | #221 |
| society clinical oncology | #221 |
| ornithine decarboxylase odc | #221 |
| pregabalin patients | #221 |
| painful peripheral | #221 |
| primary breast cancer | #222 |
| relieving | #222 |
| neoplasms palliative | #222 |
| lymphedema patients | #222 |
| methylphenidate modafinil | #222 |
| treatment postmenopausal | #222 |
| ginkgo biloba egb | #222 |
| prospective study women | #222 |
| randomized doubleblind study | #223 |
| furoate | #223 |
| prevention patients | #224 |
| 99 months | #225 |
| quinquefolius | #225 |
| computerized physician | #225 |
| partial mastectomy | #226 |
| vaginal estrogen | #226 |
| agent patients | #226 |
| turmoil | #227 |
| bupropion | #227 |
| pain presence | #227 |
| trial | #228 |
| clinical situation | #228 |
| nondiploid | #229 |
| 200 iu | #229 |
| secondary endpoint | #229 |
| anthracycline cardiotoxicity | #230 |
| antidepressive | #230 |
| placebo 10 | #230 |
| eating disorders humans | #230 |
| physicians quality | #230 |
| hospice patients | #230 |
| akt inhibitor | #230 |
| cancer recommendations | #230 |
| editorials | #230 |
| based adjuvant | #231 |
| vitamin effects | #231 |
| rashes | #231 |
| handfoot syndrome | #232 |
| lightheadedness | #232 |
| time study | #232 |
| cachexia cytokines | #232 |
| conclusionsthe | #232 |
| fluoxetine paroxetine | #233 |
| nonpharmacologic | #233 |
| acute symptoms | #234 |
| treatment vte | #234 |
| women hot | #234 |
| thirty women | #234 |
| 4 doses | #234 |
| tamoxifen neoplasms chemotherapy | #235 |
| sucralfate | #235 |
| 375 day | #235 |
| day response | #235 |
| arm 95 | #235 |
| relieve | #235 |
| effective treatments | #236 |
| premenopausal patients | #237 |
| placebo gel | #237 |
| postoperative monitoring | #238 |
| letrozole patients | #238 |
| antiemetics | #238 |
| flash | #238 |
| survivors treatment | #238 |
| incidence grade | #238 |
| adjuvant 5 | #239 |
| menopause middle | #239 |
| overexpressing metastatic | #239 |
| methodswomen | #239 |
| oncology clinic | #239 |
| chemotherapy placebo | #239 |
| nonpharmacologic interventions | #239 |
| improved bioavailability | #239 |
| cachexia syndrome | #240 |
| treatment breast cancer | #240 |
| neoadjuvant therapy surgery | #240 |
| oral complications | #240 |
| independent tests | #241 |
| participants randomized | #242 |
| stinging | #242 |
| small doses | #243 |
| aged paclitaxel | #243 |
| tetracycline | #244 |
| epoetin alfa | #245 |
| 3 arms | #245 |
| appetite stimulants | #246 |
| adjuvant oxaliplatin | #246 |
| common practice | #246 |
| efficacy placebo | #247 |
| mouthwashes | #248 |
| cachexia cancer | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| item scores | #250 |
| survivors adult | #250 |
| randomized sham | #250 |
| loss bmd | #250 |
| patients physical | #251 |
| major problems | #251 |
| 689 | #251 |
| menopause women | #252 |
| coasting | #252 |
| topic vitamin | #252 |
| armodafinil | #253 |
| randomised studies | #253 |
| primary point | #253 |
| nasal spray | #254 |
| moderate degree | #254 |
| average intensity | #254 |
| chemotherapy breast | #255 |
| recurrence registries | #255 |
| prospective clinical | #256 |
| longitudinal followup | #256 |
| antidepressant | #257 |
| therapy women | #257 |
| cancer treatment | #257 |
| neoplasms randomized | #257 |
| new therapeutic approaches | #258 |
| pretreatment levels | #258 |
| women treated | #258 |
| dyspareunia | #258 |
| rigors | #259 |
| hydrochloride | #259 |
| inhibitors treatment | #260 |
| tube cancer | #260 |
| opioid doseresponse relationship | #260 |
| common problem | #261 |
| repeated measures | #261 |
| patients cancer | #261 |
| 1 baseline | #261 |
| chronic post | #262 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| months treatment | #263 |
| management options | #263 |
| dosage levels | #263 |
| decision framework | #263 |
| hematinics | #264 |
| phytogenic | #264 |
| duloxetine placebo | #264 |
| treatment oxaliplatin | #264 |
| outcome administration | #265 |
| recommendations quality | #265 |
| preoperative mri | #266 |
| treatmentrelated deaths | #266 |
| treatment cancer | #267 |
| individual items | #267 |
| paresthesia | #267 |
| surgery adjuvant | #267 |
| substantiation | #267 |
| placebo 8 weeks | #267 |
| impact quality | #268 |
| adult cancer survivors | #268 |
| 208 patients | #269 |
| signaled | #270 |
| ginkgo biloba | #270 |
| nausea | #270 |
| patients rash | #270 |
| estrogen antagonists | #271 |
| moderate correlations | #271 |
| patients octreotide | #271 |
| 80 90 | #271 |
| performance status patients | #272 |
| dna test | #272 |
| treatment 95 | #272 |
| bridged ring | #272 |
| distressing | #272 |
| weekly | #272 |
| control trials | #272 |
| score baseline | #272 |
| placebo‐controlled trial | #273 |
| abstinence rates | #273 |
| sham treatment | #274 |
| oncology clinical trials | #274 |
| dryness | #274 |
| valeriana | #275 |
| gross disease | #275 |
| induced cisplatin | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| perspiration | #278 |
| treatment breast | #278 |
| patients hospice | #279 |
| prominent | #279 |
| patients symptoms | #279 |
| biomarkers disease humans | #279 |
| therapeutic options | #279 |
| cimicifuga | #279 |
| cholinergic antagonists | #280 |
| patients frequency | #280 |
| individual patient | #280 |
| cartilage patients | #280 |
| breast cancer outcomes | #280 |
| zoledronic acid patients | #281 |
| psychometric testing | #281 |
| doxorubicin cyclophosphamide | #281 |
| antidepressive agents | #282 |
| chamomile | #282 |
| stage colon | #282 |
| greater severity | #284 |
| women effects | #284 |
| completed questionnaires | #284 |
| gabapentin treatment | #285 |
| smoking abstinence | #285 |
| early discontinuation | #286 |
| fatigue crf | #286 |
| paps | #287 |
| colorectal lung | #287 |
| female hormone | #287 |
| function quality | #287 |
| symptoms function | #287 |
| acid adult | #287 |
| weeks patients | #287 |
| aromatase inhibitor therapy | #288 |
| hot flush | #288 |
| life survival | #290 |
| eligible patients | #291 |
| discouraged | #292 |
| clinical trial participation | #292 |
| qualitative approach | #292 |
| common symptom | #292 |
| treatment target | #292 |
| mucositis oral | #293 |
| 1636 | #294 |
| cbdca | #294 |
| weight gain patients | #294 |
| pain symptoms | #294 |
| vinca alkaloids | #295 |
| monographs | #295 |
| citalopram | #295 |
| testosterone supplementation | #295 |
| bone loss patients | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| patients entered | #298 |
| aspirin placebo | #298 |
| questionnaires treatment | #298 |
| peripheral nervous | #299 |
| feet | #299 |
| neoplasms cyclophosphamide | #299 |
| inhibitors ais | #300 |
| radiation dermatitis | #300 |
| hypothetical scenarios | #300 |
| treated combination | #301 |
| shooting | #301 |
| survival trials | #302 |
| octreotide | #302 |
| nogalamycin | #302 |
| treatment serum | #303 |
| stage grade | #303 |
| acute neurotoxicity | #303 |
| nausea vomiting | #304 |
| subscale scores | #304 |
| symptoms pain | #304 |
| schedule female | #305 |
| complementary therapies | #305 |
| placebo groups | #305 |
| prime time | #305 |
| prospective clinical trial | #305 |
| global quality life | #306 |
| factg | #306 |
| prochlorperazine | #307 |
| aromatase inhibitor | #307 |
| shortread | #307 |
| placebo treatment | #307 |
| inflammatory breast cancer | #307 |
| aged cancer | #308 |
| neoplasms chemotherapy | #308 |
| apixaban | #308 |
| drug embryo | #308 |
| darbepoetin alfa | #309 |
| zoledronic acid | #310 |
| studies double | #310 |
| advanced cancer | #311 |
| riskstratification | #311 |
| individual subject | #311 |
| lung docetaxel | #311 |
| cancer receiving | #311 |
| placebo‐controlled | #312 |
| epoetin | #312 |
| testosterone placebo | #312 |
| patients cycle | #313 |
| musculoskeletal symptoms | #313 |
| cancer adjuvant | #314 |
| syndrome aps | #314 |
| or10 | #314 |
| new primary | #315 |
| operative chemotherapy | #315 |
| article evidence | #316 |
| organoplatinum | #316 |
| symptoms breast | #317 |
| ambulatory patients | #317 |
| blinded | #317 |
| sesame oil | #317 |
| bfi | #317 |
| double‐blind | #317 |
| rivaroxaban patients | #318 |
| irox | #319 |
| efficacy treatment | #319 |
| informed decisions | #321 |
| dietary counseling | #322 |
| life differences | #322 |
| thromboembolism anticoagulants | #323 |
| smokers nicotine | #324 |
| glutamine humans | #324 |
| monthly intervals | #324 |
| preventing | #325 |
| nsclc chemotherapy | #326 |
| breast radiotherapy | #326 |
| titrate | #327 |
| patients ductal carcinoma | #327 |
| compared baseline | #327 |
| continuation phase | #328 |
| conducted evaluate | #329 |
| treatment 1 year | #329 |
| oral nutritional supplements | #329 |
| lymphedema | #329 |
| vte cancer patients | #329 |
| patients resected | #329 |
| antagonists female | #329 |
| potential efficacy | #330 |
| patients nasal | #330 |
| future clinical trials | #330 |
| arms | #330 |
| controlled clinical | #330 |
| polymerase inhibitor | #331 |
| cancer ontario | #332 |
| lozenge | #332 |
| diagnosed primary | #332 |
| 80 anemia | #334 |
| placebo patients | #334 |
| patients daily | #334 |
| time disease | #335 |
| relative benefits | #336 |
| pain scale | #336 |
| 128 patients | #336 |
| paclitaxel therapy | #336 |
| ongoing clinical | #336 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| sublingual | #337 |
| survival 5 years | #338 |
| surveillance guidelines | #338 |
| discernible | #339 |
| flutamide | #340 |
| order entry | #340 |
| treatment proportion | #341 |
| mastectomy radiotherapy | #341 |
| patients 4 weeks | #341 |
| eligible participants | #341 |
| fallopian tube cancer | #342 |
| cancer cachexia | #342 |
| osteopenia osteoporosis | #342 |
| society clinical | #343 |
| tooth disease | #343 |
| diseases quality | #343 |
| pilot randomized | #344 |
| clinicians patients | #345 |
| epha5 | #345 |
| skeletal neoplasms | #345 |
| mk2206 | #346 |
| clinical problems | #346 |
| accruing | #346 |
| adverse events groups | #347 |
| therapy pain | #347 |
| coumarin | #347 |
| mucositis patients | #348 |
| antineoplastic therapy | #349 |
| sham acupuncture | #349 |
| adjuvant folfox | #350 |
| induced acute | #350 |
| baseline quality | #350 |
| vast majority | #350 |
| dehydroepiandrosterone dhea | #351 |
| dose schedule | #351 |
| treatment citalopram | #351 |
| study therapy | #352 |
| paclitaxel | #353 |
| response letter | #353 |
| endodermal sinus | #353 |
| patientreported outcomes | #353 |
| cancer life | #355 |
| letrozole | #355 |
| risedronate | #355 |
| pain baseline | #356 |
| vomiting | #359 |
| adjuvant colonic | #359 |
| skin toxicities | #359 |
| wellknown | #360 |
| clin oncol | #360 |
| potential benefit | #360 |
| ductal situ carcinoma | #360 |
| cryotherapy | #360 |
| diaries | #361 |
| began | #361 |
| direct oral | #362 |
| pelvic radiation | #362 |
| nonpharmacological | #363 |
| calculators | #363 |
| cancer surveillance | #363 |
| pain measures | #363 |
| flaxseed | #363 |
| ovarian suppression | #363 |
| cddp | #365 |
| completing | #365 |
| ovarian fallopian | #365 |
| local prognosis receptor | #365 |
| docetaxel paclitaxel | #365 |
| management cancer | #366 |
| patients delayed | #366 |
| bioavailable testosterone | #366 |
| pain cancer | #366 |
| optimal frequency | #366 |
| scalp | #367 |
| weeks study | #368 |
| scale 0 | #368 |
| 5‐year | #368 |
| aged neoplasms | #369 |
| scheduled | #369 |
| hrt risk | #370 |
| cancer received | #371 |
| skeletalrelated events | #371 |
| gamma aminobutyric acid | #372 |
| orally daily | #372 |
| skin toxicity | #373 |
| 5fluorouracil 5fu | #373 |
| symptoms patients | #373 |
| ecogps | #374 |
| irreversible damage | #374 |
| paclitaxel dose | #374 |
| clinical oncology | #374 |
| resected stage | #374 |
| ovarian failure | #374 |
| −005 | #375 |
| women breast | #376 |
| therapy based | #376 |
| decreasing | #376 |
| blood test | #377 |
| medroxyprogesterone acetate | #377 |
| assessable patients | #378 |
| humans specificity | #378 |
| polyneuropathy | #378 |
| drowsiness | #378 |
| week patients | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| fura | #381 |
| telerehabilitation | #381 |
| loss skeletal | #381 |
| 4 treatment | #382 |
| leucovorin | #383 |
| organoplatinum compounds | #383 |
| unacceptable toxicity | #383 |
| patients capecitabine | #384 |
| adverse event | #384 |
| 402 | #384 |
| trials involving | #384 |
| target dose | #384 |
| function pain | #384 |
| disputes | #384 |
| leptin patients | #385 |
| 5fluorouracil leucovorin | #385 |
| conservation agents | #385 |
| fourths | #386 |
| density conservation | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| glutathione gsh | #390 |
| treatment women | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| adjuvant trials | #394 |
| 4 weeks | #394 |
| dying patients | #394 |
| early palliative | #395 |
| life breast | #396 |
| discontinuation rates | #396 |
| cytotoxics | #397 |
| humans mastectomy | #397 |
| ring compounds | #397 |
| olanzapine | #397 |
| performance score | #397 |
| paired tests | #398 |
| patients randomly | #398 |
| 1280 | #398 |
| life data | #399 |
| withdrew | #400 |
| questionnaires treatment outcome | #400 |
| fatty acid supplementation | #400 |
| chemotherapy colorectal | #400 |
| peripheral neurotoxicity | #400 |
| intramuscular | #400 |
| assigned | #401 |
| estrogen receptors biomarkers | #401 |
| 8090 | #401 |
| 3 cohorts | #401 |
| entered | #402 |
| evidencebased | #402 |
| loe | #402 |
| sadenosyllmethionine | #403 |
| acid female | #403 |
| female humans life | #403 |
| 5 weeks | #405 |
| baseline demographics | #406 |
| female fluorouracil | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| patients 5fu | #411 |
| life aged | #411 |
| topic neoplasms | #412 |
| female hemorrhage humans | #412 |
| ornithine decarboxylase | #414 |
| regimens patients | #414 |
| based chemotherapy | #415 |
| oxaliplatin based | #415 |
| pain qol | #415 |
| acetate | #415 |
| placebo 2 | #415 |
| oncology neoplasms | #416 |
| patient factors | #416 |
| carboplatin patients | #416 |
| delayed | #417 |
| platinum agents | #417 |
| gabapentinoids | #417 |
| prospective pilot | #417 |
| receiving | #418 |
| adjuvant hormonal therapy | #419 |
| case series patients | #419 |
| nighttime sleep | #419 |
| metastatic breast cancer | #419 |
| 0 4 | #419 |
| antiemetic prophylaxis | #420 |
| cancer purpose | #421 |
| study entry | #421 |
| controlled pilot | #421 |
| tamoxifen women | #421 |
| tcl1a | #421 |
| fourth week | #422 |
| severities | #422 |
| selfreported symptoms | #422 |
| directed therapy | #422 |
| adequately | #423 |
| arm 2 | #423 |
| pyridones | #423 |
| 5 trials | #423 |
| neurophysiologic | #424 |
| anastrozole | #425 |
| tamoxifen | #425 |
| androgen ablation | #425 |
| complementary alternative | #426 |
| ongoing clinical trials | #426 |
| baseline 6 weeks | #427 |
| prevention vte | #427 |
| treating patients | #428 |
| primary peritoneal | #428 |
| gain adult | #428 |
| greater percentage | #429 |
| creatine | #429 |
| desipramine | #430 |
| adjectives | #430 |
| laser therapy | #431 |
| detection colorectal | #431 |
| fatigue humans | #431 |
| contraindicated | #431 |
| methodsa | #431 |
| glycitein | #431 |
| hgb | #431 |
| diploid tumors | #432 |
| symptom management | #432 |
| joint symptoms | #433 |
| sunscreen | #433 |
| antiseizure | #433 |
| cancer tamoxifen | #434 |
| purpose objectives | #434 |
| resultsone | #434 |
| 115 patients | #434 |
| oral calcium | #435 |
| 1157 | #436 |
| olanzapine treatment | #436 |
| topic treatment | #436 |
| pains | #436 |
| nutrition cancer | #436 |
| anthracyclinebased chemotherapy | #438 |
| absolute terms | #438 |
| clinical cancer | #438 |
| nodenegative breast cancer | #439 |
| administration cutaneous | #440 |
| postoperative follow | #440 |
| diminish | #441 |
| expected survival | #441 |
| neoplasms cancer | #441 |
| yoga | #442 |
| vasomotor | #442 |
| hgpin | #444 |
| baseline 1 month | #444 |
| doxorubicin drug administration | #445 |
| loss aged | #445 |
| screening colorectal | #445 |
| receive | #445 |
| life efficacy | #445 |
| preoperative breast | #445 |
| agents antineoplastic | #446 |
| marie | #446 |
| acid aged | #447 |
| day dexamethasone | #447 |
| treatment regimen | #447 |
| patients qol | #448 |
| european organization | #448 |
| patients weight | #448 |
| 2 months | #448 |
| climacteric | #449 |
| estrogen therapy | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| cancer symptoms | #452 |
| baseline 4 weeks | #452 |
| outline | #453 |
| study feasibility | #453 |
| arms arm | #454 |
| nodepositive breast cancer | #454 |
| postmenopause | #455 |
| dhea | #455 |
| 5fu patients | #456 |
| geranium | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| enforced | #461 |
| questionnaires terminology | #461 |
| patients venous thromboembolism | #461 |
| 6 weeks | #462 |
| patients baseline | #462 |
| helpful | #462 |
| cytokines patients | #462 |
| potential interventions | #463 |
| increased weight | #463 |
| therapy stage | #464 |
| clin | #468 |
| asco | #468 |
| cancer institute | #468 |
| referral centers | #469 |
| radiation enteritis | #469 |
| lung humans | #469 |
| sexual distress | #470 |
| consensus guideline | #470 |
| esophagitis patients | #471 |
| treatment options patients | #471 |
| purposethis | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| subscale | #474 |
| 432 | #474 |
| pilocarpine | #474 |
| hormonal replacement therapy | #475 |
| groups 6 months | #475 |
| symptoms menopause | #475 |
| uncertain | #476 |
| preliminary studies | #477 |
| appears | #477 |
| single item | #477 |
| placebo 24 weeks | #478 |
| clinical decision making | #478 |
| 95 placebo | #479 |
| onco | #479 |
| variables age | #479 |
| iii colon | #479 |
| doubleblind study | #479 |
| vitamin placebo | #480 |
| alopecia | #480 |
| enrollment patients | #480 |
| osteoporosis osteopenia | #481 |
| crc 95 | #482 |
| moderatetosevere | #482 |
| higher dose | #483 |
| adjuvant therapy | #484 |
| reluctance | #484 |
| endpoints included | #485 |
| locoregional disease | #485 |
| tpn | #485 |
| neurotoxicity patients | #485 |
| cure | #486 |
| 655 | #486 |
| taqman pcr | #488 |
| blind | #488 |
| induced neuropathic | #489 |
| doselimiting toxicity | #491 |
| pain scores | #491 |
| estrogen deprivation | #491 |
| cancer cardiovascular disease | #492 |
| plant preparations | #493 |
| combined modality treatment | #493 |
| primary breast | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| fentanyl humans | #500 |
| patients breast cancer | #500 |
| “ ” | #501 |
| received placebo | #501 |
| placebo‐controlled study | #502 |
| kps | #502 |
| pilot studies | #502 |
| life questionnaires survivors | #502 |
| metastatic cancer | #503 |
| loss patients | #504 |
| mesonephroma | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| smoking nicotine | #511 |
| placebo trial | #511 |
| preventative | #512 |
| breast diseases | #513 |
| therapy aged | #513 |
| trials data | #513 |
| nonmetastatic breast cancer | #514 |
| advance planning acp | #514 |
| flic | #514 |
| evidencebased interventions | #515 |
| premature menopause | #516 |
| letrozole treatment | #516 |
| women receiving | #516 |
| serum albumin levels | #517 |
| outcome antineoplastic | #517 |
| acute diarrhea | #519 |
| achievements | #520 |
| pain medications | #520 |
| cbcs | #521 |
| eflornithine | #521 |
| gamma aminobutyric | #522 |
| pharmaceutic | #522 |
| poorer quality life | #523 |
| symptoms fatigue | #525 |
| mastectomy middle | #525 |
| chills | #525 |
| resultsto | #527 |
| adverse events placebo | #528 |
| prophylactic therapy | #528 |
| controlled crossover | #528 |
| cmf | #529 |
| phytogenic area | #529 |
| abt888 | #529 |
| patients clinical trial | #529 |
| therapy prostate | #530 |
| radiodermatitis | #531 |
| pregabalin | #531 |
| centrally | #531 |
| oncologists | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| medications treatment | #536 |
| patients evaluated | #536 |
| antineoplastic agents | #537 |
| superficial bladder | #538 |
| agents chemotherapy | #538 |
| study week | #538 |
| weeks therapy | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| pain patients | #543 |
| dehydroepiandrosterone | #543 |
| topic severity | #543 |
| risedronic | #544 |
| week 6 | #544 |
| pain score | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| dabrafenib trametinib | #552 |
| 3 95 | #552 |
| axonal transport | #553 |
| hypesthesia | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| dysplastic lesions | #556 |
| evaluable | #556 |
| neoplasms drug | #556 |
| co2 laser | #556 |
| regular aspirin | #556 |
| abh | #557 |
| 300 day | #557 |
| vasomotor symptoms | #559 |
| emesis | #560 |
| 80000 | #560 |
| rbc transfusions | #560 |
| reported outcomes | #560 |
| methylphenidate | #561 |
| moisturizer | #561 |
| day treatment | #561 |
| mesna | #562 |
| hands | #564 |
| lmwh patients | #564 |
| time detection | #565 |
| method drug | #565 |
| induced cold | #565 |
| trial data | #566 |
| treatment periods | #566 |
| 4 8 | #567 |
| survival stage | #567 |
| supportive cancer | #567 |
| 11 months | #568 |
| calgb | #569 |
| adjuvant clinical trials | #569 |
| therapy primary | #569 |
| scientifically | #569 |
| topic treatment outcome | #571 |
| decarboxylase odc | #571 |
| lower dose | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| methods systematic review | #580 |
| patients candidates | #580 |
| refute | #580 |
| hwe | #581 |
| treatment phase | #581 |
| breakthrough pain | #583 |
| paced | #583 |
| paracentesis | #584 |
| life questionnaire | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| drug toxicity | #587 |
| neoplasms nutritional | #587 |
| paclitaxel carboplatin | #588 |
| multiple cancers | #589 |
| aged occult | #589 |
| limited efficacy | #589 |
| muscle cramps | #589 |
| oxaliplatin patients | #589 |
| emotional functioning | #589 |
| taxane chemotherapy | #590 |
| osteopenia | #590 |
| aminobutyric | #590 |
| acrin | #591 |
| ablation therapy | #592 |
| median time progression | #592 |
| crossover trial | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| compounded | #596 |
| pentoxifylline | #596 |
| fatigue female | #597 |
| exanthema | #597 |
| sst2 | #597 |
| radiotherapy breast | #597 |
| multisite | #598 |
| topic depressive disorder | #598 |
| publication administration | #599 |
| patients mastectomy | #599 |
| initial surgery | #599 |
| effects breast | #600 |
| patients etanercept | #600 |
| thromboembolism vte | #600 |
| statistically differences | #601 |
| oral solution | #601 |
| discretion | #601 |
| patient decision | #601 |
| health providers | #601 |
| 1093 | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| exposed patients | #604 |
| cancer survivors | #604 |
| anthracycline based | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| 16 women | #608 |
| toes | #608 |
| chemotherapy administration | #608 |
| iron supplementation | #609 |
| agents antidepressive | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| 2 95 | #613 |
| pilot | #613 |
| updated analysis | #614 |
| montanide | #615 |
| qol baseline | #616 |
| animal data | #616 |
| 118 patients | #617 |
| humans quality | #617 |
| commonly | #618 |
| antacid | #620 |
| appetite | #620 |
| persistent symptoms | #621 |
| urinary frequency | #621 |
| aic | #621 |
| follow median | #622 |
| itching | #625 |
| analyzable | #626 |
| gangliosides humans | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| biological targets | #634 |
| mistletoe | #634 |
| month patients | #637 |
| female sexual function | #638 |
| serum hepcidin | #640 |
| assessment cancer | #640 |
| dose placebo | #640 |
| eligible | #641 |
| poorer quality | #642 |
| hormonal aromatase | #643 |
| inhibitors breast | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| palliative quality | #647 |
| nasal symptoms | #647 |
| 300 patients | #648 |
| malignant melanomas | #648 |
| symptoms | #649 |
| syndrome acute | #649 |
| flushes | #651 |
| doses patients | #651 |
| method humans | #651 |
| sores | #651 |
| appeared | #652 |
| opioid analgesic | #653 |
| limiting toxicity | #653 |
| dose limiting | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| patients chemotherapy | #662 |
| colorectal adenocarcinoma | #662 |
| 62 months | #663 |
| 95 − | #665 |
| alternative treatments | #666 |
| cancer prospective | #666 |
| neoplasms patient | #666 |
| active agent | #666 |
| nonparametric surveys | #667 |
| life radiotherapy | #667 |
| levetiracetam | #668 |
| cancer treatments | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| paclitaxel docetaxel | #671 |
| marie tooth | #671 |
| axonopathy | #674 |
| p00004 | #674 |
| 1822 | #674 |
| pain adult | #674 |
| pharmacologic management | #675 |
| maintenance disorders | #675 |
| induced cognitive | #676 |
| racially | #676 |
| 5 consecutive | #678 |
| patients standard | #678 |
| controlled study | #679 |
| routine follow | #680 |
| diethylstilbestrol | #681 |
| reported outcome | #681 |
| purpose report | #682 |
| study samples | #684 |
| oncology practice | #685 |
| highdose melphalan | #685 |
| popularly | #685 |
| deprivation therapy | #686 |
| therapy cancer | #687 |
| fluorouracil leucovorin | #687 |
| sulindac | #688 |
| neurologic injury | #688 |
| practice settings | #688 |
| charcot marie | #688 |
| pharmacological targeting | #692 |
| life survivors | #692 |
| rescue medication | #693 |
| guideline update | #693 |
| phlebitis | #694 |
| administration schedule | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| desmethyl | #699 |
| potential benefits | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| postmenopausal | #704 |
| chemopreventive agent | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| erythropoiesis stimulating | #712 |
| randomized studies | #712 |
| 160 | #712 |
| tube neoplasms | #714 |
| newer agents | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| lowmolecularweight heparin | #717 |
| inflammatory breast | #717 |
| endorsement | #719 |
| convened | #719 |
| ameliorate | #720 |
| data baseline | #722 |
| erythropoietin female | #722 |
| cyclophosphamide methotrexate | #725 |
| 6 months 95 | #725 |
| humans neoplasms | #725 |
| palliative medicine | #725 |
| therapeutic equivalency | #727 |
| physicians predictive | #728 |
| 4 hours | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| induced human | #731 |
| odc activity | #731 |
| study treatment | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| vinca | #735 |
| medroxyprogesterone | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| induced neurotoxicity | #738 |
| chemotherapy women | #738 |
| opd | #739 |
| mirtazapine | #741 |
| 4 weeks patients | #742 |
| prescribing practices | #742 |
| locoregional therapy | #742 |
| fist | #744 |
| armamentarium | #745 |
| women placebo | #745 |
| baseline 1 year | #745 |
| patients breast | #747 |
| ecog | #748 |
| bone loss | #748 |
| trials patients | #749 |
| chemotherapy initiation | #749 |
| superficial bladder cancer | #750 |
| psychostimulant | #750 |
| alfa | #750 |
| 271 | #750 |
| rand | #752 |
| cervical dysplasia | #752 |
| compared placebo | #753 |
| complementary medicine | #753 |
| radiation skin | #754 |
| 4·2 | #754 |
| antigen levels | #754 |
| oct2 | #754 |
| secondary points | #755 |
| trouble | #755 |
| 46 | #755 |
| paclitaxel chemotherapy | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| rifngamma | #759 |
| reduction pain | #759 |
| local anesthetics | #759 |
| sulfasalazine | #760 |
| prostate adenocarcinoma | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| 81 patients | #766 |
| seventy patients | #766 |
| occult blood | #766 |
| acid 4 | #768 |
| medroxyprogesterone acetate mpa | #768 |
| neoplasms prospective | #768 |
| humans imidazoles | #769 |
| baseline pain | #769 |
| activity breast | #770 |
| actual | #770 |
| sensory neuropathy | #771 |
| breast carcinoma ductal | #772 |
| modified radical mastectomy | #772 |
| sweating | #772 |
| relatedness | #772 |
| women enrolled | #773 |
| premenopausal women | #773 |
| keratinocyte growth factor | #773 |
| primary endpoint | #773 |
| neoplasms breast | #774 |
| fifty patients | #774 |
| patients colon | #774 |
| emla | #774 |
| 10 day | #774 |
| aged peripheral | #775 |
| acupuncture therapy | #776 |
| octreotide treatment | #776 |
| 257 | #777 |
| oral administration | #777 |
| charcot | #778 |
| p00002 | #778 |
| gsm | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| cutaneous administration | #785 |
| skin conductance | #785 |
| benefits patients | #785 |
| prognostic survival | #787 |
| enoxaparin | #788 |
| management | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| women reported | #793 |
| subsequent cycles | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| life outcomes | #801 |
| neuralgia pain | #801 |
| clinical questions | #801 |
| osteoporosis women | #802 |
| erythropoiesisstimulating agents | #802 |
| day 3 | #804 |
| lack efficacy | #804 |
| randomized phase trial | #804 |
| glutathione | #805 |
| primary points | #805 |
| effects patients | #806 |
| double | #806 |
| opioid analgesia | #807 |
| 894 | #807 |
| placebotreated patients | #808 |
| etoposide cisplatin | #808 |
| continue | #808 |
| 80 antineoplastic | #808 |
| 3 day | #808 |
| 0025 | #809 |
| complete response | #811 |
| odc | #812 |
| abrogate | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| eastern cooperative | #820 |
| agents clinical | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| statisticians | #826 |
| tolerated | #826 |
| 148 patients | #827 |
| cancer control | #828 |
| rasch model | #828 |
| suggestive | #830 |
| administration oral | #830 |
| placebo 6 months | #830 |
| cancer phase | #830 |
| dabrafenib | #832 |
| neoplasms bone | #832 |
| subset analysis | #833 |
| humans medical | #833 |
| similarities differences | #835 |
| advanced malignancies | #836 |
| 366 | #836 |
| mandelic | #837 |
| prognosis quality | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| herbal products | #846 |
| adverse events aes | #846 |
| p006 | #847 |
| global qol | #848 |
| 142 patients | #848 |
| detection rates | #849 |
| eortc | #850 |
| toxicities | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| stage ovarian | #853 |
| oncotype | #853 |
| n55 | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| vaginal bleeding | #859 |
| assessment management | #859 |
| taxoids | #859 |
| stratification patients | #860 |
| published data | #860 |
| strongest | #864 |
| etidronic | #866 |
| placebo baseline | #868 |
| patients trial | #868 |
| unacceptable | #868 |
| efficacious | #873 |
| jellies | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| symptomatic women | #880 |
| phytogenic carcinoma | #880 |
| nonpharmacological interventions | #880 |
| midlife women | #881 |
| study placebo | #883 |
| antineoplastic | #883 |
| 450 | #883 |
| monoclonal antineoplastic agents | #885 |
| neurotoxic | #889 |
| mitigates | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| caa | #894 |
| cancer guidelines | #894 |
| control arm | #896 |
| completed | #900 |
| oxy | #901 |
| neoplasms hormone | #901 |
| women hormone | #902 |
| nodal status | #903 |
| percent | #903 |
| inconvenience | #903 |
| nmsc | #904 |
| 00006 | #905 |
| chemotherapy response | #905 |
| survival surgery | #905 |
| provided | #905 |
| hospices | #909 |
| increased risk death | #910 |
| chemotherapeutic | #910 |
| cancer studies | #913 |
| national cancer | #914 |
| weight maintenance | #914 |
| norepinephrine reuptake | #915 |
| life cancer patients | #916 |
| paroxetine | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| advanced cancer patients | #921 |
| mouth mucosa | #921 |
| evidence practice | #923 |
| manuscripts | #924 |
| population cohort | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| upper extremities | #929 |
| oral dosing | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| electronic health record | #939 |
| serotonin uptake | #939 |
| visual analogue | #940 |
| treatment symptoms | #940 |
| 138 patients | #942 |
| advanced adenoma | #943 |
| uptake inhibitors | #943 |
| high‐risk | #943 |
| patient population | #944 |
| colorectal adenomas | #944 |
| letter editor | #944 |
| iii topic | #945 |
| beckman | #945 |
| gp100 | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| jci | #954 |
| orally | #954 |
| evaluating | #955 |
| participating centers | #955 |
| cooperative oncology | #957 |
| hfs | #958 |
| rheumatologic | #958 |
| aloe vera | #958 |
| adjuvant therapies | #958 |
| leukopenia | #959 |
| erythropoietic | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| pjnk | #963 |
| trpm8 | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| table | #972 |
| earlystage disease | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| restarted | #977 |
| olmsted county | #977 |
| hypercalcemia | #978 |
| 1 10 | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| antidotes | #984 |
| 150 | #984 |
| 1 week | #984 |
| patients venous | #989 |
| threequarters | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| bother | #1003 |
| mayo | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| fatigue patients | #1028 |
| enteritis | #1028 |
| urogenital | #1030 |
| delayed treatment | #1031 |
| alternative treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| postural control | #1044 |
| prx | #1044 |
| randomized trial patients | #1046 |
| prevention intervention | #1047 |
| colorectal tumor | #1047 |
| patients safety | #1047 |
| substantial | #1050 |
| nutritional supplementation | #1051 |
| frey | #1051 |
| life | #1053 |
| 30 40 | #1053 |
| postchemotherapy | #1056 |
| doxorubicin female humans | #1056 |
| minority | #1057 |
| feeding eating | #1059 |
| primary analysis | #1059 |
| osteoporosis treatment | #1059 |
| 10 weeks | #1060 |
| day study | #1061 |
| tricyclic | #1061 |
| fruitful | #1063 |
| prospective validation | #1063 |
| oncologist | #1063 |
| endocrine resistance | #1064 |
| 347 | #1064 |
| loss weight | #1066 |
| ongoing studies | #1066 |
| therapy | #1069 |
| disappointing | #1069 |
| suggested | #1069 |
| practical guidance | #1070 |
| metastatic lung | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| nccn | #1078 |
| monoclonal humans | #1078 |
| concurrent chemotherapy | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| prompted | #1089 |
| breast cancer recurrence | #1089 |
| duloxetine | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| palonosetron | #1095 |
| postoperative surveillance | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| favor | #1099 |
| intravenous iron | #1099 |
| agents treatment | #1100 |
| previous chemotherapy | #1100 |
| functional ability | #1100 |
| 54 | #1103 |
| phytoestrogens | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| interprofessional relations | #1126 |
| cancer trials | #1126 |
| unpleasant | #1127 |
| prilocaine | #1127 |
| dmc | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| clinician | #1133 |
| patients versus | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| 25 micrograms | #1139 |
| opioid therapy | #1139 |
| hormonal therapy | #1140 |
| practice guideline | #1140 |
| cancer | #1141 |
| purposeto | #1144 |
| inhibit | #1144 |
| egb | #1146 |
| cancer pain | #1146 |
| randomized crossover | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| purpose determine | #1150 |
| premature ovarian failure | #1150 |
| shark | #1150 |
| 730 | #1153 |
| nervousness | #1153 |
| smoking prevention | #1154 |
| detrimental | #1154 |
| hormonal | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| rinse | #1162 |
| 22 | #1162 |
| doac | #1163 |
| educate | #1164 |
| toxicity assessment | #1167 |
| purposethis study | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| painful | #1174 |
| therapy estrogens | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| prior treatment | #1189 |
| international consensus | #1189 |
| mastectomy breast | #1190 |
| acetate treatment | #1190 |
| usage | #1193 |
| gained | #1196 |
| estrogen replacement therapy | #1197 |
| olmsted | #1197 |
| diary | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| partial responses | #1204 |
| male smokers | #1204 |
| 552 | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| satisfied | #1212 |
| breast cancer | #1212 |
| induced skin | #1213 |
| communication skills | #1215 |
| 611 | #1215 |
| patients pts | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| sexuality | #1219 |
| precludes | #1219 |
| secondary endpoints | #1219 |
| 8 week | #1221 |
| higher numbers | #1223 |
| phase clinical trial | #1223 |
| limiting | #1224 |
| thighs | #1227 |
| editor | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| primary melanomas | #1232 |
| 8 weeks | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| discontinue | #1235 |
| randomized phase | #1235 |
| tricyclic antidepressants | #1241 |
| clinical syndrome | #1241 |
| baseline values | #1245 |
| review data | #1248 |
| day 2 | #1248 |
| symptoms diagnosis | #1248 |
| decided | #1249 |
| female sexual | #1250 |
| etiologies | #1250 |
| bedtime | #1252 |
| postmenopausal women | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| diphosphonates | #1258 |
| thromboembolism patients | #1258 |
| combination docetaxel | #1258 |
| patients 4 | #1259 |
| trametinib | #1259 |
| hypochromic | #1259 |
| kidney dysfunction | #1260 |
| rasch | #1260 |
| pain medication | #1261 |
| neurologic humans | #1263 |
| doubts | #1263 |
| dna ploidy | #1265 |
| tumor promotion | #1265 |
| esophagitis | #1266 |
| sae | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| drug double | #1272 |
| qol scores | #1272 |
| short form36 | #1273 |
| situ carcinoma ductal | #1273 |
| patients families | #1274 |
| preoperative chemotherapy | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| tamoxifen patients | #1279 |
| taxanes | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| adjuvant therapy patients | #1289 |
| opposed | #1289 |
| cyclophosphamide doxorubicin | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| acupuncture treatment | #1294 |
| cochran | #1294 |
| data clinical | #1296 |
| prevalence severity | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| abstinent | #1307 |
| 8 cycles | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| melanoma antigen | #1315 |
| gsh | #1315 |
| biotech | #1315 |
| breast biopsy | #1317 |
| contacted | #1318 |
| durations | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| oncology patients | #1321 |
| chemotherapeutic agents | #1321 |
| investigative | #1321 |
| controlled | #1321 |
| pain interference | #1322 |
| primary outcome measure | #1322 |
| patients quality | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| life scores | #1328 |
| patient physician | #1328 |
| cardiac toxicity | #1329 |
| agents colorectal | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| breast cancer women | #1347 |
| platinum compounds | #1347 |
| colonoscopic | #1350 |
| experienced | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| cancer experience | #1353 |
| benefit patients | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| patients colon cancer | #1382 |
| n29 | #1382 |
| n32 | #1382 |
| duplicates | #1386 |
| hydrazines | #1387 |
| mastectomy | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| polyneuropathies | #1407 |
| rifn | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| viscum | #1416 |
| wilcoxon | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| sleep initiation | #1424 |
| subjective symptoms | #1424 |
| noncompliance | #1424 |
| biloba | #1425 |
| therapy initiation | #1426 |
| methodsdata | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| hormonal treatment | #1431 |
| aromatase | #1431 |
| and or | #1432 |
| weight heparin | #1433 |
| 5fu | #1433 |
| radiation injuries | #1434 |
| statistically difference | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| goserelin | #1445 |
| proctitis | #1445 |
| aminobutyric acid | #1446 |
| ehrs | #1447 |
| postacute | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| treatment pain | #1454 |
| nccn guidelines | #1454 |
| patients ovarian | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| effective management | #1461 |
| dna testing | #1461 |
| individual patients | #1461 |
| adjuvant treatment | #1463 |
| aged quality | #1466 |
| life cancer | #1466 |
| discrepancies | #1467 |
| haloperidol humans | #1467 |
| network meta | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| hormone dependent | #1477 |
| life treatment | #1477 |
| substantial proportion | #1479 |
| resultsa | #1479 |
| lower extremities | #1483 |
| oral aged | #1484 |
| tumor promoter | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| paclitaxel cisplatin | #1501 |
| resultsafter | #1501 |
| mpa | #1509 |
| colon cancer patients | #1510 |
| anti anxiety | #1510 |
| perimenopause | #1513 |
| gynecologic cancer | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| hair loss | #1523 |
| biweekly | #1523 |
| efficacy | #1523 |
| diagnosed cancer | #1525 |
| p0024 | #1525 |
| oncology | #1526 |
| root ganglion | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cytotoxic agents | #1537 |
| cck8 | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| blind randomized | #1562 |
| male breast | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| iii disease | #1576 |
| pharmacologic treatment | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| rivaroxaban | #1583 |
| crushed | #1583 |
| patients small | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| dissent | #1593 |
| image body | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| trpa1 | #1600 |
| stratification | #1600 |
| therapy cyclophosphamide | #1602 |
| aged cross | #1603 |
| completion | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| 2003 | #1652 |
| controlled phase | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| breast cancer patients | #1667 |
| populationbased cohort | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| anticancer therapy | #1693 |
| neoplasms practice | #1693 |
| weight patients | #1694 |
| percent patients | #1695 |
| stopping | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| randomization | #1698 |
| patients bone | #1698 |
| nootropic | #1698 |
| morpholines | #1700 |
| symptom distress | #1701 |
| patients control | #1701 |
| endpoint | #1703 |
| glutamine | #1705 |
| enrolled patients | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| chemotherapy patients | #1709 |
| 595 | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| effects cancer | #1726 |
| human epidermal | #1726 |
| selective estrogen | #1728 |
| referral consultation | #1728 |
| testosterone treatment | #1729 |
| 652 | #1729 |
| nineteen | #1730 |
| neuropathic pain | #1731 |
| orchiectomy | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| topical | #1746 |
| p450 cyp2d6 | #1746 |
| ≥10 | #1749 |
| oxcarbazepine | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| neoplasms early | #1754 |
| unique challenges | #1754 |
| treatment data | #1762 |
| greater reduction | #1762 |
| insufficient evidence | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| grade 2 | #1766 |
| massage | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| 95 0 | #1781 |
| clinical endpoints | #1781 |
| objective responses | #1784 |
| fingers | #1784 |
| behavioral interventions | #1785 |
| lignans | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| life assessment | #1791 |
| anorectic | #1791 |
| survival outcomes patients | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| primary therapy | #1796 |
| alternative medicine | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| acetylcarnitine | #1803 |
| treatment cycles | #1803 |
| severe toxicity | #1804 |
| median survival time | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| agents female | #1813 |
| 16 patients | #1813 |
| breast surgery | #1816 |
| trpm | #1818 |
| evidencebased recommendations | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| 327 | #1823 |
| cancer women | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| ganglion neurons | #1831 |
| humans neoplasm | #1831 |
| longterm survival patients | #1835 |
| neoplasms prognosis | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| comprehensive cancer | #1851 |
| months 12 | #1851 |
| neuropathic | #1853 |
| 23 months | #1853 |
| patients prognosis | #1853 |
| dermatological | #1853 |
| providers patients | #1857 |
| aged postmenopause | #1858 |
| cancer types | #1858 |
| initial dose | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| humans pain | #1873 |
| europe female humans | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| induced pain | #1879 |
| resultsa total | #1879 |
| antigen colorectal | #1881 |
| analysis adult | #1881 |
| musculoskeletal pain | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| keratinocyte | #1891 |
| questionnaires time | #1891 |
| schedules | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| stellate | #1899 |
| problematic | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| health personnel attitude | #1946 |
| prematurely | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| primary aim | #1971 |
| iii breast | #1971 |
| warrant | #1972 |
| surveillance colonoscopy | #1974 |
| articles | #1974 |
| initiating | #1975 |
| estrogen replacement | #1978 |
| clinical patients | #1978 |
| hand foot | #1979 |
| intravaginal | #1982 |
| collaborative | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| androgen antagonists | #1994 |
| cancer patient | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| phytotherapy plant | #2018 |
| form36 | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| critics | #2025 |
| perimenopausal | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| relaxation therapy | #2069 |
| cancer population | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| hb level | #2075 |
| daily | #2075 |
| safety pharmacokinetics | #2075 |
| vinblastine | #2076 |
| 50 reduction | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| younger women | #2087 |
| iii | #2087 |
| patients caregivers | #2088 |
| advanced cancers | #2090 |
| nursing practice | #2090 |
| antidote | #2090 |
| cco | #2094 |
| major bleeding | #2094 |
| 66 years | #2097 |
| weekly paclitaxel | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| orally administered | #2111 |
| tmt | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| bmd lumbar spine | #2121 |
| ≥2 | #2121 |
| 5fluorouracil | #2122 |
| treatment study | #2124 |
| 96 patients | #2124 |
| journals | #2125 |
| mildly | #2126 |
| hb levels | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| secondary objectives | #2136 |
| 525 | #2136 |
| concerned | #2136 |
| egfr inhibitors | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| evidence efficacy | #2166 |
| baseline | #2166 |
| treatment acute | #2169 |
| anemic | #2169 |
| aloe | #2175 |
| women | #2177 |
| pain syndromes | #2179 |
| album | #2179 |
| worst | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| dose intensity | #2208 |
| 455 | #2208 |
| prescription drugs | #2210 |
| female head | #2210 |
| age race | #2210 |
| 1 7 | #2212 |
| hypnosis | #2213 |
| ensuing | #2213 |
| weight loss | #2214 |
| recurrences | #2220 |
| 1–4 | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| 9 weeks | #2235 |
| osteonecrosis jaw | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| adrenal axis | #2247 |
| failed | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| 1 year patients | #2285 |
| oophorectomy | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| life illness | #2301 |
| therapy adt | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| polymerase inhibitors | #2310 |
| conclusionthe | #2310 |
| patch | #2311 |
| recommendation | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| baclofen | #2327 |
| 74 | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| burning | #2333 |
| 36 | #2333 |
| mastectomy segmental | #2333 |
| modest | #2334 |
| toxicity | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| opioid analgesics | #2347 |
| society | #2347 |
| androgen deprivation | #2349 |
| improve quality | #2349 |
| 46 patients | #2352 |
| curve analysis | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| cyp2d6 | #2365 |
| density bmd | #2365 |
| baseline treatment | #2367 |
| increased risks | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| 266 | #2405 |
| counteract | #2405 |
| titles | #2406 |
| treatment baseline | #2407 |
| inadequate | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| poor performance | #2419 |
| rectal cancer patients | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| 5 patients | #2425 |
| advanced prostate cancer | #2425 |
| limited evidence | #2426 |
| symptom scores | #2426 |
| debate | #2433 |
| 761 | #2436 |
| 71 patients | #2437 |
| practiced | #2437 |
| patients crc | #2439 |
| estrogen deficiency | #2439 |
| response evaluation | #2442 |
| acupuncture | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| factor inhibitors | #2469 |
| assessment scale | #2469 |
| fallopian | #2474 |
| 207 | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| locoregional | #2510 |
| 61 | #2510 |
| ginkgo | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| asked | #2542 |
| amitriptyline | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| treatment methods | #2556 |
| 12 24 | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| randomised clinical trial | #2567 |
| telopeptide | #2567 |
| nitriles | #2568 |
| reuptake | #2570 |
| treatment selection | #2570 |
| earlystage breast cancer | #2573 |
| stage small | #2573 |
| conjunctivitis | #2574 |
| trials | #2592 |
| secondary analyses | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| antineoplastic combined | #2624 |
| outcome united | #2624 |
| consented | #2626 |
| apr | #2626 |
| suspicious | #2627 |
| dorsal root | #2629 |
| symptoms quality | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| thromboembolism | #2657 |
| races | #2657 |
| 0001 patients | #2657 |
| attenuate | #2662 |
| scores | #2663 |
| total parenteral nutrition | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| chemotherapy protocols | #2745 |
| modestly | #2745 |
| thermal hyperalgesia | #2748 |
| multiple factors | #2749 |
| acp | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| 1 4 | #2775 |
| male neoplasms | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| paraneoplastic syndromes | #2790 |
| pooled data | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| ascites | #2794 |
| isoflavones | #2794 |
| agents | #2797 |
| complete data | #2799 |
| nv | #2801 |
| thrice | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| opioids | #2844 |
| meeting | #2844 |
| 38 | #2845 |
| primary outcomes | #2845 |
| cancer aged | #2854 |
| cohen | #2857 |
| n31 | #2857 |
| linseed | #2859 |
| breakthrough | #2859 |
| neoplasms | #2860 |
| pharmacogenomic | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| breaths | #2867 |
| activity level | #2867 |
| purposethe | #2869 |
| anticipate | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| task force | #2886 |
| 5 years patients | #2886 |
| ellipse | #2893 |
| p04 | #2895 |
| survival dose | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| prior | #2931 |
| condylomata | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| dosing regimens | #2949 |
| review articles | #2949 |
| identifier | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| calories | #2991 |
| started | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| n5 | #3012 |
| objective response | #3012 |
| topically | #3013 |
| discomfort | #3014 |
| time progression | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| her2 status | #3041 |
| reuptake inhibitors | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| risk colorectal | #3058 |
| relief | #3058 |
| dukes | #3058 |
| tumor activity | #3066 |
| outcome measure | #3067 |
| curve auc | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| vera | #3111 |
| bmd | #3111 |
| cancer female humans | #3111 |
| 66 | #3116 |
| neurokinin1 | #3121 |
| 26 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| supportive | #3185 |
| current approaches | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| joint committee | #3225 |
| intervention trial | #3225 |
| 39 | #3226 |
| nonsmallcell lung cancer | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| therapy combination | #3260 |
| itch | #3260 |
| intervention patients | #3263 |
| oral mucosa | #3264 |
| designed | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| root ganglia | #3287 |
| 2030 | #3287 |
| 80 antibodies | #3288 |
| 695 | #3290 |
| 885 | #3290 |
| lymphoma patients | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| treatment placebo | #3320 |
| impression | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| acuminata | #3334 |
| 171 | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| bone metastases | #3370 |
| doubt | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| screening methods | #3446 |
| 012 | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| utilizing | #3463 |
| 64 patients | #3463 |
| sprays | #3464 |
| survival benefits | #3468 |
| listed | #3468 |
| pts | #3468 |
| anthracyclines | #3471 |
| chemotherapy radiation | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| phase topic | #3583 |
| correlational | #3583 |
| survival women | #3583 |
| 135 | #3586 |
| carboplatin paclitaxel | #3586 |
| oestrogen | #3587 |
| patients experiences | #3588 |
| chemotherapy cycles | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| life qol | #3608 |
| objective measures | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| benefits risks | #3620 |
| survival cancer | #3620 |
| ≥30 | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| colon cancer | #3650 |
| ordinal | #3650 |
| patients adjuvant chemotherapy | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| 673 | #3682 |
| sigmoidoscopy | #3682 |
| preceded | #3685 |
| proportion | #3686 |
| 580 | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| terminal | #3811 |
| anesthetics | #3811 |
| hormone replacement | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| intramuscularly | #3834 |
| patients experienced | #3834 |
| 136 | #3839 |
| 16 weeks | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| seventy | #3854 |
| blinding | #3854 |
| patients grade | #3855 |
| sharks | #3855 |
| internally | #3858 |
| treatment metastatic | #3861 |
| 23 | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| publication clinical trials | #3940 |
| myoclonus | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| lasting | #4002 |
| weight | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| audio | #4034 |
| patients intervention | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| prostatic | #4062 |
| erythropoietin | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| conjunction | #4069 |
| cancer therapy | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| favoring | #4126 |
| noninfiltrating | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| topic practice patterns | #4138 |
| definitions | #4138 |
| tablets | #4138 |
| femoral neck | #4139 |
| malignant melanoma | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| depressants | #4210 |
| cancer bone | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| contraindication | #4258 |
| neoplasms colorectal | #4258 |
| treatment discontinuation | #4268 |
| serially | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| bone density | #4284 |
| survival quality | #4284 |
| day | #4285 |
| utilized | #4289 |
| inconsistencies | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| reductions | #4326 |
| prednisolone | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| primary endpoints | #4331 |
| healthy women | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| neoplasms combined | #4359 |
| institute | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| repeatedly | #4402 |
| drug combinations | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| 80 breast | #4431 |
| studies colorectal | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| improve patient | #4446 |
| day patients | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| 80 | #4465 |
| pain measurement | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| daily activities | #4523 |
| 5 | #4523 |
| sedation | #4529 |
| ganglion | #4530 |
| ductal breast | #4530 |
| gynecologic | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| stimulant | #4536 |
| disabling | #4536 |
| natural | #4537 |
| sphingolipids | #4537 |
| drug effects | #4540 |
| diarrhea | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| rescue therapy | #4564 |
| clinical | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| reliability validity | #4575 |
| 4 | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| risk bleeding | #4591 |
| hydroxytryptamine | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| daily dose | #4647 |
| 6 12 | #4647 |
| neuropathies | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| adpribose | #4665 |
| dose chemotherapy | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| ” | #4734 |
| mediastinum | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| corticosteroid | #4806 |
| 009 | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| cancer compared | #4818 |
| improved quality | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| symptom burden | #4836 |
| multicenter | #4836 |
| carcinoma small | #4837 |
| bridged | #4837 |
| seer program | #4841 |
| tubulin | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| screening tool | #4956 |
| sensitization | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| genistein | #5084 |
| karnofsky performance | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| version | #5104 |
| pyrimidinones | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| physical therapy | #5131 |
| reducing | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| humans lung | #5249 |
| article | #5249 |
| insomnia | #5255 |
| conventionally | #5257 |
| patients time | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| low molecular | #5270 |
| caring | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| alkaloids | #5335 |
| anticipated | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| perceived | #5359 |
| sensation | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| stage iii | #5423 |
| officinalis | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| sensory | #5638 |
| treatment approaches | #5638 |
| lung carcinoma | #5642 |
| new therapies | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| renewed | #5694 |
| dexamethasone | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| complete | #5730 |
| specialist | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| tumor breast | #5762 |
| tumor stage | #5762 |
| interruption | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| carcinoma situ | #5783 |
| nicotine | #5783 |
| mucous | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| 405 | #5877 |
| interfere | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| insulinlike growth factor | #6013 |
| 1977 | #6013 |
| prognostic indicator | #6018 |
| descriptions | #6019 |
| minute | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| chemotherapy radiotherapy | #6041 |
| 0013 | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| psychotropic drugs | #6280 |
| disclosure | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| benzhydryl | #6302 |
| insignificant | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| aged | #6372 |
| fentanyl | #6372 |
| 2007 | #6385 |
| venous thromboembolism vte | #6385 |
| infusions | #6393 |
| epidermal growth | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| pittsburgh | #6439 |
| psychotropic | #6439 |
| entire | #6440 |
| multinational | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| intraluminal | #6471 |
| 75 | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| hemoglobins | #6612 |
| l3 | #6612 |
| decisions | #6614 |
| 287 | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| pellet | #6646 |
| guidelines | #6646 |
| crf | #6648 |
| patients health | #6651 |
| hormone receptor | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| caloric | #6694 |
| erectile dysfunction | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| radiotherapy chemotherapy | #6702 |
| hypothesized | #6702 |
| ketamine | #6710 |
| consecutive | #6717 |
| colorectal cancer patients | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| quit | #6751 |
| replacement therapy | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| longest | #6801 |
| frequently | #6801 |
| search strategy | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| fulfilled | #6810 |
| controlled studies | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| cbd | #6942 |
| factors breast | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| skin temperature | #6981 |
| regressions | #6981 |
| ais | #6986 |
| wearing | #6990 |
| quiet | #6990 |
| calorie | #6990 |
| definition | #6994 |
| 35 | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| interested | #7067 |
| patients 1 | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| prostate cancer | #7130 |
| neoplasms female | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| outpatients | #7296 |
| neoplasms primary | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| evaluates | #7353 |
| superficial | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| rfs | #7416 |
| curative | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| receptor agonists | #7436 |
| emphasis | #7436 |
| confirmatory | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| ploidy | #7624 |
| interval | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| monitored | #7699 |
| 1 day | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| 021 | #7725 |
| surveys | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| administration | #7744 |
| washout | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| ago | #7927 |
| impacted | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| comparing | #7956 |
| 5year survival | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| genders | #8063 |
| intractable | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| patients adult | #8249 |
| regard | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| year follow | #8372 |
| pharmacogenetics | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| undergoing | #8422 |
| preparations | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 3 trial | #8482 |
| 37 | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| morphine | #8637 |
| estrogen receptors | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| single nucleotide polymorphisms | #8700 |
| notable | #8700 |
| threatening | #8705 |
| molecular markers | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| real | #8800 |
| mouth | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| favored | #9020 |
| longer | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| 94 | #9317 |
| systematic literature | #9317 |
| possess | #9332 |
| 15 | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| mechanisms action | #9383 |
| acceptable | #9383 |
| ambulatory | #9385 |
| drug female | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| partial response | #9454 |
| definitive | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| cancer crc | #9542 |
| 500 | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| monoclonal humanized | #9791 |
| priority | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| clinical outcomes patients | #9872 |
| avoid | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| reactions female | #10007 |
| prescribing | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| changed | #10400 |
| survival dfs | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| longitudinal studies | #10522 |
| mineral density | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| counselling | #10617 |
| doxorubicin | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| enter | #10757 |
| anticoagulants | #10757 |
| fat mass | #10763 |
| iiia | #10779 |
| median duration | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| clinic | #10803 |
| 182 | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| smoking | #11105 |
| international society | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| sick | #11135 |
| practice guidelines | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| clinical signs | #11439 |
| apparent | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| 235 | #11509 |
| caregivers | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| 024 | #11855 |
| definite | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| referral | #11997 |
| 1998 | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| sodium channel | #12270 |
| peri | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| fourteen | #12657 |
| rank test | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| humans logistic | #13082 |
| future | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| epidemiologic | #13262 |
| humans lymphatic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| agonists | #13630 |
| improves | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| marked | #13813 |
| 18 years | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| lung cancer | #14080 |
| substances | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| protective | #14195 |
| modality | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| states aged | #14282 |
| careful | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| instance | #14341 |
| analysis performed | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| produces | #14420 |
| 144 | #14420 |
| 4 patients | #14436 |
| extremity | #14440 |
| nodal | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| episodes | #14626 |
| 09 | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| adult | #14729 |
| 008 | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| neoplasm | #14762 |
| 15 years | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| assessments | #15187 |
| colonoscopy | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 197 | #15404 |
| 131 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| option | #15749 |
| updated | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| local | #15882 |
| glandular | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| phenomenon | #16013 |
| usa | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| 161 | #16209 |
| analysis survival | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| neoadjuvant | #16222 |
| supported | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| neurotransmitter | #16320 |
| detection cancer | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| diagnostic imaging | #16418 |
| improvements | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| rarely | #16886 |
| major | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| iron deficiency | #17162 |
| diseasefree survival | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| inhibitor | #19177 |
| mood | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| 2005 | #22223 |
| authors | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| imaging mri | #23033 |
| diverse | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2017 | #23997 |
| 2011 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
Bericht ausführen | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| Bekannt für Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| Bekannt für Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| Bekannt für Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| Bekannt für Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| Bekannt für Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| Bekannt für Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| Bekannt für Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| Bekannt für Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| Bekannt für Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| Bekannt für Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| Bekannt für Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| Bekannt für Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| Bekannt für Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
Schlüsselpersonen für Hot Flashes
Top -Kols der Welt
Wählen Sie einen Suchphrase aus hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:Expertenwirkung
Konzepte für welcheCharles L Loprinzihat direkten Einfluss:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:KOL -Auswirkungen
Konzepte im Zusammenhang mit der Arbeit anderer Autoren, für diefor which Charles L Loprinzi hat Einfluss:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
Ist das dein Profil? Fordern Sie Ihr Profil an URL kopieren Einbetten Sie den Link zu Ihrem Profil ein |